

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**  
FOR THE INTERIM PERIOD JANUARY 1-SEPTEMBER 30, 2023  
CONSOLIDATED FINANCIAL STATEMENTS AND NOTES

<b>CONTENTS</b>	<b>Page</b>	
<b>INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION</b>	1 – 2	
<b>INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS</b>	3	
<b>INTERIM CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE INCOME</b>	4	
<b>INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY</b>	5-6	
<b>INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS</b>	7	
<b>DISCLOSURES FOR THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b>		
NOTE 1	GROUP'S ORGANIZATION AND NATURE OF OPERATIONS	8-11
NOTE 2	BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS	11-32
NOTE 3	BUSINESS MERGERS	33-34
NOTE 4	SEGMENT REPORTING	35-36
NOTE 5	CASH AND CASH EQUIVALENTS	37
NOTE 6	FINANCIAL INVESTMENTS	37-38
NOTE 7	FINANCIAL BORROWINGS	39-41
NOTE 8	ACCOUNTS RECEIVABLES AND PAYABLES	42-43
NOTE 9	OTHER RECEIVABLES AND PAYABLES	43
NOTE 10	DERIVATIVE INSTRUMENTS	44
NOTE 11	INVENTORIES	45
NOTE 12	PREPAID EXPENSES AND DEFERRED INCOME	45
NOTE 13	INVESTMENTS VALUED BY EQUITY METHOD	46
NOTE 14	INVESTMENT PROPERTIES	47
NOTE 15	CURRENT TAX ASSETS	48
NOTE 16	RIGHT OF USE ASSETS	48
NOTE 17	TANGIBLE ASSETS	49-50
NOTE 18	INTANGIBLE ASSETS EXCLUDING GOODWILL	51-52
NOTE 19	PROVISIONS, CONTINGENT ASSETS AND LIABILITIES	53-54
NOTE 20	EMPLOYEE BENEFIT OBLIGATION PROVISIONS	55-56
NOTE 21	OTHER ASSETS AND LIABILITIES	56
NOTE 22	EQUITY	57-59
NOTE 23	GOODWILL	60
NOTE 24	REVENUE AND COST OF SALES	61
NOTE 25	GENERAL ADMINISTRATIVE AND MARKETING EXPENSES	62-63
NOTE 26	OTHER OPERATING INCOME AND EXPENSES	64
NOTE 27	INCOME AND EXPENSES FROM INVESTING ACTIVITIES	65
NOTE 28	FINANCIAL INCOME AND EXPENSES	66
NOTE 29	INCOME TAXES	67-69
NOTE 30	EARNINGS PER SHARE	70
NOTE 31	RELATED PARTY DISCLOSURES	70-72
NOTE 32	NATURE AND LEVEL OF RISKS ARISING FROM FINANCIAL INSTRUMENTS	73-78
NOTE 33	FINANCIAL INSTRUMENTS (FAIR VALUE AND HEDGE ACCOUNTING DISCLOSURES)	79
NOTE 34	EVENTS AFTER THE BALANCE SHEET DATE	80

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**SEPTEMBER 30, 2023**  
**INTERIM FINANCIAL POSITION STATEMENT (BALANCE SHEET)**  
*(Amounts are in Turkish Lira (TL) unless otherwise indicated)*

	Note	Current Period	Previous Period
		Not Audited	Audited
Type of Financial Statement		Consolidated	Consolidated
Period		September 30, 2023	December 31, 2022
<b>ASSETS</b>			
<b>Current Assets</b>		<b>12.636.581.535</b>	<b>7.333.662.376</b>
Cash and Cash Equivalents	5	1.614.119.922	1.519.704.774
Financial Investments	6	1.772.947.222	1.047.908.349
Accounts Receivables		5.355.397.406	2.946.838.510
- Accounts Receivables from Related Parties	8,31	569.550	101.569.916
- Accounts Receivables from Third Parties	8	5.354.827.856	2.845.268.594
Other Receivables		103.977.112	57.687.020
- Other Receivables from Third Parties	9	103.977.112	57.687.020
Derivative Financial Instruments	10	410.090.493	144.075.641
Inventories	11	3.042.355.883	1.283.277.033
Prepaid Expenses	12	260.573.851	214.208.401
Current Period Tax Assets	15	5.492.236	87.611.727
Other Current Assets	21	71.627.410	32.350.921
<b>Non-Current Assets</b>		<b>4.307.092.858</b>	<b>3.283.457.037</b>
Financial Investments	6	177.711.724	-
Accounts Receivables		10.197.097	10.197.097
- Accounts Receivables from Third Parties	8	10.197.097	10.197.097
Other Receivables		1.199.458	832.953
- Other Receivables from Third Parties	9	1.199.458	832.953
Investments valued by Equity Method	13	8.557.673	7.808.666
Investment Properties	14	968.000	968.000
Right of Use Assets	16	4.770.303	5.985.770
Tangible Assets	17	3.158.008.721	2.420.638.382
Intangible Assets		550.031.480	562.178.671
- Goodwill	3,23	44.014.405	43.251.838
- Other Intangible Assets	18	506.017.075	518.926.833
Prepaid Expenses	12	29.144.095	23.502.406
Deferred Tax Assets	29	366.504.307	251.345.092
<b>TOTAL ASSETS</b>		<b>16.943.674.393</b>	<b>10.617.119.413</b>

*The accompanying notes are an integral component of these interim consolidated financial statements.*

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**SEPTEMBER 30, 2023**  
**INTERIM FINANCIAL POSITION STATEMENT (BALANCE SHEET)**

(Amounts are in Turkish Lira (TL) unless otherwise indicated)

	Note	Current Period	Previous Period
		Not Audited	Audited
Type of Financial Statement		Consolidated	Consolidated
Period		September 30, 2023	December 31, 2022
<b>SOURCES</b>			
<b>Short-Term Liabilities</b>		<b>11.105.158.033</b>	<b>5.972.906.227</b>
Short-Term Borrowings		4.333.214.794	1.620.635.261
- Bank Loans	7	4.333.214.794	1.620.635.261
Short-Term Portion of Long-Term Borrowings	7	903.491.198	772.569.856
Accounts Payables		5.579.748.660	3.083.354.814
- Accounts Payables to Related Parties	8,31	3.167.544	4.117.214
- Accounts Payables to Third Parties	8	5.576.581.116	3.079.237.600
Employee Benefit Payables	20	28.164.060	11.158.749
Other Payables		60.576.850	205.591.252
- Other Payables to Related Parties	9,31	59.151.600	205.312.078
- Other Payables to Third Parties	9	1.425.250	279.174
Derivative Financial Instruments	10	-	65.554.675
Deferred Income	12	127.868.543	100.421.758
Short-Term Provisions		7.457.298	17.333.752
- Short-Term Provisions for Employee Benefits	20	6.018.625	3.032.935
- Other Short-Term Provisions	19	1.438.673	14.300.817
Other Short-Term Liabilities	21	64.636.630	96.286.110
<b>Long-Term Liabilities</b>		<b>1.748.849.601</b>	<b>1.434.567.344</b>
Long-Term Borrowings	7	929.434.566	839.994.216
Long-Term Provisions		31.253.770	24.505.736
- Long-Term Provisions for Employee Benefits	20	31.253.770	24.505.736
Deferred Tax Liabilities	29	788.161.265	570.067.392
<b>Total Equity</b>		<b>4.089.666.759</b>	<b>3.209.645.842</b>
Capital Receipts		190.970.000	190.970.000
Share Repurchased (-)		(128.911.890)	(64.567.763)
Share Premiums (Discounts)		445.982.390	15.269.029
Other Accumulated Comprehensive Income (Expense) Not To Be Reclassified To Profit or Loss		1.560.754.371	1.574.556.913
- Revaluation Increase / (Decrease) on Tangible Assets		1.576.653.012	1.583.492.480
- Remeasurement Gain on Defined Benefit Plans		(15.652.446)	(8.791.736)
- Shares of Other Comprehensive Income of Investments Valued by Equity Method That Will Not Be Reclassified to Profit or Loss		(246.195)	(143.831)
Other Accumulated Comprehensive Income (Expense) to be Reclassified to Profit or Loss		340.359.560	144.881.024
- Cumulative Translation Adjustment		340.359.560	144.881.024
Restricted Reserves		209.113.864	78.622.024
Retained Earnings		878.847.165	162.445.260
Net Period Profit		304.989.910	1.107.469.355
Shareholder Equity		3.802.105.370	3.209.645.842
Non-Controlling Interest		287.561.389	-
<b>TOTAL SOURCES</b>		<b>16.943.674.393</b>	<b>10.617.119.413</b>

The accompanying notes are an integral component of these interim consolidated financial statements.

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**FOR THE INTERIM PERIOD JANUARY 1-SEPTEMBER 30, 2023**  
**CONSOLIDATED STATEMENT OF PROFIT OR LOSS**

(Amounts are in Turkish Lira (TL) unless otherwise indicated)

	Note	Current Period		Previous Period	
		Not Audited		Not Audited	
Type of Financial Statement		Consolidated	Consolidated	Consolidated	Consolidated
Period		January 1- September 30, 2023	July 1- September 30, 2023	January 1- September 30, 2022	July 1- September 30, 2022
Revenue	4,24	24.054.685.530	10.226.231.709	13.703.582.080	4.189.242.985
Cost of Sales	4,24	(22.721.045.152)	(9.600.576.993)	(12.346.539.776)	(3.862.176.249)
<b>GROSS PROFIT/LOSS</b>		<b>1.333.640.378</b>	<b>625.654.716</b>	<b>1.357.042.304</b>	<b>327.066.736</b>
General Administrative Expenses	25	(149.445.603)	(54.849.757)	(68.907.655)	(23.261.763)
Marketing Expenses	25	(571.401.417)	(265.958.039)	(287.789.182)	(107.933.623)
Research and Development Expenses	25	(519.355)	(181.150)	(53.177)	(32.335)
Other Operating Income	26	1.689.316.666	371.100.094	1.341.248.255	739.395.352
Other Operating Expenses	26	(994.286.134)	(182.002.942)	(1.039.845.189)	(587.745.946)
<b>OPERATING PROFIT/LOSS</b>		<b>1.307.304.535</b>	<b>493.762.922</b>	<b>1.301.695.356</b>	<b>347.488.421</b>
Income from Investing Activities	27	400.974.602	273.380.579	552.167.424	22.923.638
Expenses from Investing Activities	27	(1.648.422)	(854.516)	(2.523.434)	(845.908)
Impairment Determined as Per IFRS 9	27	(3.310.221)	(1.449.278)	(2.482.024)	(986.991)
Reversal of Gains (Losses) and Impairment Losses					
Share of Profit (Loss) of Investments Valued by Equity Method	13	3.963.862	2.659.334	2.549.747	950.896
<b>OPERATING PROFIT/LOSS BEFORE FINANCING EXPENSES</b>		<b>1.707.284.356</b>	<b>767.499.041</b>	<b>1.851.407.069</b>	<b>369.530.056</b>
Financing Revenues	28	1.257.820.150	152.254.502	816.654.418	153.198.688
Finance Expenses	28	(2.487.762.991)	(740.541.819)	(1.430.887.995)	(384.602.049)
<b>PRETAX CONTINUING OPERATING INCOME</b>		<b>477.341.515</b>	<b>179.211.724</b>	<b>1.237.173.492</b>	<b>138.126.695</b>
<b>Tax Expense / Income from Continuing Operations</b>		<b>(109.828.035)</b>	<b>(38.810.683)</b>	<b>(159.109.809)</b>	<b>18.438.298</b>
Period Tax Expense / Income	29	(75.230.935)	(46.078.036)	(123.388.029)	(38.698.381)
Deferred Tax Expense / Income	29	(34.597.100)	7.267.353	(35.721.780)	57.136.679
<b>PROFIT (LOSS) FOR THE PERIOD</b>		<b>367.513.480</b>	<b>140.401.041</b>	<b>1.078.063.683</b>	<b>156.564.993</b>
<b>Distribution of Profit (Loss) for the Period</b>		<b>367.513.480</b>	<b>140.401.041</b>	<b>1.078.063.683</b>	<b>156.564.993</b>
Non-Controlling Interests		62.523.570	26.294.479	-	-
Equity Shares		304.989.910	114.106.562	1.078.063.683	156.564.993
<b>Earnings / (loss) per share</b>		<b>1,6974</b>	<b>0,6390</b>	<b>5,9130</b>	<b>0,8778</b>
Earnings per Share from Continuing Operations	30	1,6974	0,6390	5,9130	0,8778

The accompanying notes are an integral component of these interim consolidated financial statements.

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**FOR THE INTERIM PERIOD JANUARY 1-SEPTEMBER 30, 2023**  
**CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE INCOME**

(Amounts are in Turkish Lira (TL) unless otherwise indicated)

	Note	Current Period		Previous Period	
		Not Audited	Not Audited	Revised	Revised
Type of Financial Statement		Consolidated	Consolidated	Consolidated	Consolidated
Period		January 1- September 30, 2023	July 1- September 30, 2023	January 1- September 30, 2022	July 1- September 30, 2022
<b>Period Profit</b>		<b>367.513.480</b>	<b>140.401.041</b>	<b>1.078.063.683</b>	<b>156.564.993</b>
<b>Not to be Reclassified to Profit or Loss</b>		<b>172.169.244</b>	<b>(8.866.609)</b>	<b>200.892.022</b>	<b>(3.142.078)</b>
Revaluation Increase (Decrease) on Tangible Assets		183.523.967	(2.520.489)	202.606.603	-
Gain (Loss) on Remeasurement of Defined Benefit Plans		(11.218.237)	(6.279.693)	(1.683.457)	(3.115.168)
Shares of Other Comprehensive Income of Investments Valued by Equity Method Not to be Reclassified to Profit or Loss		(136.486)	(66.427)	(31.124)	(26.910)
<b>Taxes on Other Comprehensive Income Not To Be Reclassified To Profit or Loss</b>		<b>(73.336.718)</b>	<b>(55.733.808)</b>	<b>(1.185.129)</b>	<b>31.338.971</b>
Gain (Loss) on Remeasurement of Defined Benefit Plans, Tax Effect		2.886.300	1.898.777	387.195	716.489
Revaluation Increase (Decrease) on Tangible Assets, Tax Effect		(76.257.140)	(57.652.694)	(1.579.483)	30.616.293
Share of Other Comprehensive Income of Associates and Joint Ventures Accounted for Using the Equity Method that will not be Reclassified to Profit or Loss, Tax Effect		34.122	20.109	7.159	6.189
<b>To be Reclassified to Profit or Loss</b>		<b>195.478.536</b>	<b>36.509.349</b>	<b>91.597.587</b>	<b>32.314.977</b>
Foreign Currency Translation Adjustments		195.478.536	36.509.349	91.597.587	32.314.977
<b>Taxes on Other Comprehensive Income to be Reclassified to Profit or Loss</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Deferred Tax (Expense) Income		-	-	-	-
<b>OTHER COMPREHENSIVE INCOME (EXPENSE)</b>		<b>294.311.062</b>	<b>(28.091.068)</b>	<b>291.304.480</b>	<b>60.511.870</b>
<b>TOTAL COMPREHENSIVE INCOME/(EXPENSE)</b>		<b>661.824.542</b>	<b>112.309.973</b>	<b>1.369.368.163</b>	<b>217.076.863</b>
<b>Distribution of Total Comprehensive Income</b>		<b>661.824.542</b>	<b>112.309.973</b>	<b>1.369.368.163</b>	<b>217.076.863</b>
Non-Controlling Interests		92.221.563	22.761.174	-	-
Equity Shares		569.602.979	89.548.799	1.369.368.163	217.076.863

The accompanying notes are an integral component of these interim consolidated financial statements.

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**FOR THE INTERIM PERIOD JANUARY 1-SEPTEMBER 30, 2023**  
**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
*(Amounts are in Turkish Lira (TL) unless otherwise indicated)*

Note	Capital Receipts	Repurchased Shares	Share Premiums /Discounts	Other Comprehensive Income or Expense Not To Be Reclassified To Profit or Loss			Other Comprehensive Income or Expense to be Reclassified to Profit or Loss	Retained Earnings			Non-controlling Interests	Equity	
				Tangible Fixed Asset Revaluation Increases (Decreases)	Defined Benefit Plans Remeasurement Earnings /(Losses)	Shares of Other Comprehensive Income of Investments Valued by Equity Method Not to be Reclassified to Profit or Loss	Foreign Currency Translation Adjustments	Nonprofit Restricted Reserves	Retained Earnings/Losses	Net Period Profit/Loss			Equity Attributable to Parent Company
<b>As of 01.01.2022</b>	<b>190.970.000</b>	<b>(26.765.386)</b>	<b>15.269.029</b>	<b>252.938.157</b>	<b>(1.238.083)</b>	<b>(38.934)</b>	<b>55.993.439</b>	<b>36.867.423</b>	<b>64.604.605</b>	<b>139.595.256</b>	<b>728.195.506</b>	-	<b>728.195.506</b>
Transfers	-	-	-	-	-	-	-	3.952.224	135.643.032	(139.595.256)	-	-	-
Total Comprehensive Income (Loss)	-	-	-	201.027.120	(1.296.262)	(23.965)	91.597.587	-	-	1.078.063.683	1.369.368.163	-	1.369.368.163
- Period Profit (Loss)	-	-	-	-	-	-	-	-	-	1.078.063.683	1.078.063.683	-	1.078.063.683
- Other Comprehensive Income (Loss)	-	-	-	201.027.120	(1.296.262)	(23.965)	91.597.587	-	-	-	291.304.480	-	291.304.480
Other Amounts													
Reclassified from Accumulated Other Comprehensive Income to Retained Earnings (Losses)	-	-	-	(381.402)	-	-	-	-	381.402	-	-	-	-
Increase ( Decrease) Due to Share Repurchase Transactions	-	(37.802.377)	-	-	-	-	-	37.802.377	(37.802.377)	-	(37.802.377)	-	(37.802.377)
<b>As of 30.09.2022</b>	<b>190.970.000</b>	<b>(64.567.763)</b>	<b>15.269.029</b>	<b>453.583.875</b>	<b>(2.534.345)</b>	<b>(62.899)</b>	<b>147.591.026</b>	<b>78.622.024</b>	<b>162.826.662</b>	<b>1.078.063.683</b>	<b>2.059.761.292</b>	-	<b>2.059.761.292</b>
<b>As of 30.09.2022 Previously Reported</b>	<b>190.970.000</b>	<b>(64.567.763)</b>	<b>15.269.029</b>	<b>453.583.875</b>	<b>(2.534.345)</b>	<b>(62.899)</b>	<b>147.591.026</b>	<b>78.622.024</b>	<b>162.826.662</b>	<b>679.567.648</b>	<b>1.661.265.257</b>	-	<b>1.661.265.257</b>
<b>Corrections for Errors</b>	<b>2.5</b>									<b>398.496.035</b>	<b>398.496.035</b>	-	<b>398.496.035</b>
<b>Restated as of 30.09.2022</b>	<b>190.970.000</b>	<b>(64.567.763)</b>	<b>15.269.029</b>	<b>453.583.875</b>	<b>(2.534.345)</b>	<b>(62.899)</b>	<b>147.591.026</b>	<b>78.622.024</b>	<b>162.826.662</b>	<b>1.078.063.683</b>	<b>2.059.761.292</b>	-	<b>2.059.761.292</b>

*The accompanying notes are an integral component of these interim consolidated financial statements.*

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**FOR THE INTERIM PERIOD JANUARY 1-SEPTEMBER 30, 2023**  
**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
*(Amounts are in Turkish Lira (TL) unless otherwise indicated)*

Note	Capital Receipts	Repurchased Shares	Share Premiums /Discounts	Other Comprehensive Income or Expense Not To Be Reclassified To Profit or Loss			Other Comprehensive Income or Expense to be Reclassified to Profit or Loss	Retained Earnings						
				Tangible Fixed Asset Revaluation Increases (Decreases)	Defined Benefit Plans Remeasurement Earnings /(Losses)	Shares of Other Comprehensive Income of Investments Valued by Equity Method Not to be Reclassified to Profit or Loss	Foreign Currency Translation Adjustments	Nonprofit Restricted Reserves	Retained Earning/Loss	Net Period Profit/Loss	Equity Attributable to Parent Company	Non-controlling Interests	Equity	
<b>As of 31.12.2022 Previously Reported</b>	<b>190.970.000</b>	<b>(64.567.763)</b>	<b>15.269.029</b>	<b>1.583.492.480</b>	<b>(8.791.736)</b>	<b>(143.831)</b>	<b>144.881.024</b>	<b>78.622.024</b>	<b>162.445.260</b>	<b>712.885.211</b>	<b>2.815.061.698</b>	<b>-</b>	<b>2.815.061.698</b>	
<b>Corrections for Errors</b>	<b>2.5</b>									<b>394.584.144</b>	<b>394.584.144</b>	<b>-</b>	<b>394.584.144</b>	
<b>Restated as of 01.01.2023</b>	<b>22</b>	<b>190.970.000</b>	<b>(64.567.763)</b>	<b>15.269.029</b>	<b>1.583.492.480</b>	<b>(8.791.736)</b>	<b>(143.831)</b>	<b>144.881.024</b>	<b>78.622.024</b>	<b>162.445.260</b>	<b>1.107.469.355</b>	<b>3.209.645.842</b>	<b>-</b>	<b>3.209.645.842</b>
Transfers	-	-	-	-	-	-	-	-	68.726.324	1.038.743.031	(1.107.469.355)	-	-	-
Total Comprehensive Income (Loss)	-	-	-	76.811.707	(7.574.810)	(102.364)	195.478.536	-	-	304.989.910	569.602.979	92.221.563	661.824.542	
- Period Profit (Loss)	-	-	-	-	-	-	-	-	-	304.989.910	304.989.910	62.523.570	367.513.480	
- Other Comprehensive Income (Loss)	-	-	-	76.811.707	(7.574.810)	(102.364)	195.478.536	-	-	-	264.613.069	29.697.993	294.311.062	
Other Amounts Reclassified from Accumulated Other Comprehensive Income to Retained Earnings (Losses)	-	-	-	(13.734.676)	-	-	-	-	13.734.676	-	-	-	-	
Dividends	-	-	-	-	-	-	-	-	-	(209.152.645)	-	(209.152.645)	(20.051.746)	(229.204.391)
Increase (decrease) Due to Repurchase of Shares	-	(64.344.127)	-	-	-	-	-	-	64.344.127	(64.344.127)	-	(64.344.127)	-	(64.344.127)
Increase (Decrease) Due to Share Based Transactions	-	-	523.200.071	-	-	-	-	-	-	-	-	523.200.071	15.540.103	538.740.174
Acquisition or Disposal of Subsidiaries	-	-	-	-	-	-	-	-	-	-	-	-	1.400.012	1,400.012
Transactions with Non-Controlling Shareholders	-	-	(92.486.710)	(69.916.499)	714.100	-	-	(2.578.611)	(34.183.737)	-	(198.451.457)	198.451.457	-	
Increase (Decrease) Due to Other Changes	-	-	-	-	-	-	-	-	-	(28.395.293)	-	(28.395.293)	-	(28.395.293)
<b>As of 30.09.2023</b>	<b>22</b>	<b>190.970.000</b>	<b>(128.911.890)</b>	<b>445.982.390</b>	<b>1.576.653.012</b>	<b>(15.652.446)</b>	<b>(246.195)</b>	<b>340.359.560</b>	<b>209.113.864</b>	<b>878.847.165</b>	<b>304.989.910</b>	<b>3.802.105.370</b>	<b>287.561.389</b>	<b>4.089.666.759</b>

*The accompanying notes are an integral component of these interim consolidated financial statements.*



**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**FOR THE PERIOD JANUARY 1- SEPTEMBER 30, 2023**  
**CONSOLIDATED STATEMENT OF CASH FLOWS**

(Amounts are in Turkish Lira (TL) unless otherwise indicated)

	Note	Current Period	Previous Period
		Not Audited	Not Audited
Type of Financial Statement		Consolidated	Consolidated
Period		January 1- September 30, 2023	January 1- September 30, 2022
<b>Cash Flows from Operating Activities</b>		<b>(550.060.503)</b>	<b>(965.906.854)</b>
Period Profit (Loss)		367.513.480	1.078.063.683
- Period Profit (Loss) from Continuing Operations	22	367.513.480	1.078.063.683
Adjustments Related to Reconciliation of Net Period Profit (Loss)		41.582.915	175.871.227
- Depreciation and Amortization Expense Adjustments	16,17,18	124.282.911	68.965.236
- Adjustments for Provisions	8,20	135.251.453	933.819
- Adjustments for Bargain Purchase Gain	28	(98.145.122)	(26.401.371)
- Interest (Income) and Expense Adjustments		(222.740.985)	80.708.951
- Tax (Income) Expense Adjustments	29	102.934.658	51.664.592
Changes in Working Capital		(959.156.898)	(2.219.841.764)
- Decrease (Increase) in Financial Investments		(902.750.596)	(1.095.920.308)
- Adjustments for Decrease (Increase) in Accounts Receivables	8,31	491.546.814	(1.056.535.208)
- Adjustments for Decrease (Increase) in Other Operating Receivables	9,31	(330.253.292)	(67.968.504)
- Adjustments for Decrease (Increase) in Inventories	11	(1.759.078.850)	(273.820.715)
- Adjustments for Increase (Decrease) in Accounts Payables	8,31	2.637.920.791	1.663.854.092
- Adjustments for Increase (Decrease) in Other Operating Payables	9,31	(78.442.988)	314.375.710
- Adjustments for Other Increase (Decrease) in Working Capital		(1.018.098.777)	(1.703.826.831)
<b>Cash Flows from Investing Activities</b>		<b>(973.697.644)</b>	<b>(160.725.687)</b>
Cash Outflows for the Acquisition of Shares of Other Entities or Funds or Debt Instruments	6	(28.632.000)	-
Cash Inflows from Sale of Tangible and Intangible Assets		54.871.143	14.690.001
- Cash Inflows from Sale of Tangible Assets	17	54.323.009	14.690.001
- Cash Inflows from Sale of Intangible Assets	18	548.134	-
Cash Outflows from Acquisition of Tangible and Intangible Assets		(708.571.402)	(144.972.864)
- Cash Outflows from Acquisition of Tangible Assets	17	(705.799.240)	(141.979.406)
- Cash Outflows from Acquisition of Intangible Assets	18	(2.772.162)	(2.993.458)
Cash Advances and Payables		(59.151.600)	-
- Cash Advances and Payables Given to Related Parties	31	(59.151.600)	-
Cash Inflows / Outflows from Derivative Instruments		(235.326.275)	(31.376.898)
Received Dividends	13	3.112.490	934.074
<b>Cash Flows from Financing Activities</b>		<b>1.422.694.759</b>	<b>1.543.718.605</b>
Cash Inflows from Borrowing		6.492.858.314	2.448.420.941
- Cash Inflows from Loans	7	6.492.858.314	2.448.420.941
Cash Outflows from Debt Payments		(4.410.851.298)	(578.569.326)
- Cash Outflows from Loan Repayments	7	(4.410.851.298)	(578.569.326)
Cash Outflows Due to Debt Payments Arising from Lease Agreements		(3.347.048)	(3.203.476)
Paid Dividends		(229.204.392)	-
Interest Paid	28	(627.920.153)	(362.788.743)
Interest Received	28	201.159.336	39.859.209
<b>Net Increase (Decrease) in Cash and Cash Equivalents Before Foreign Currency Translation Adjustments</b>		<b>(101.063.388)</b>	<b>417.086.064</b>
Effect of Foreign Currency Translation Adjustments on Cash and Cash Equivalents		195.478.536	91.597.587
<b>Net Increase (Decrease) in Cash and Cash Equivalents</b>		<b>94.415.148</b>	<b>508.683.651</b>
<b>Cash and Cash Equivalents at the Beginning of the Period</b>	5	<b>1.519.704.774</b>	<b>498.900.969</b>
<b>Cash and Cash Equivalents at the End of the Period</b>	5	<b>1.614.119.922</b>	<b>1.007.584.620</b>

The accompanying notes are an integral component of these interim consolidated financial statements.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 1- GROUP'S ORGANIZATION AND NATURE OF OPERATIONS

Ulusoy Un Sanayi ve Ticaret Anonim Şirketi ('the Company') was founded in 1989 to produce, distribute, import, and export various food products made from cereals and pulses, including flour, semolina, pasta, and biscuits.

The company's main office is located at 42 Interior Door No:1 Alaçam Street, Denizevler Mahallesi, Atakum/Samsun. The following provides details of the company's branches:

Branch Name	Address
Istanbul Branch	Levent Mahallesi Şener Sokak No:5 Beşiktaş / İstanbul
Kirazlık Branch	Şabanoğlu Mahallesi Atatürk Bulvarı No:272 Tekkeköy / Samsun
Çorlu Branch	Hıdırağa İstasyon No:20/A Çorlu / Tekirdağ
Ellinci Yıl Branch	Çiftlik OSB Mahallesi 3. Cadde No:12 Tekkeköy / Samsun
Samsun Serbest Bölge Branch	Liman SB Mahallesi 1. Cadde Sasbaş Ofisler Apt. No:36/17 İlkadım / Samsun

As of September 30, 2023, the Company has an authorized capital ceiling of TL 2.5 billion. The Capital Markets Board ("CMB") has authorized the registered capital limit until 2027. December 31, 2022: 422.500.000 TL)

As of September 30, 2023, the Company's issued capital is TL 190.970.000 (One hundred ninety million nine hundred and seventy thousand Turkish Liras). This capital is divided into 22,035,000 Class A shares, 14,690,000 Class B shares, and 154,245,000 Class C shares. Each share holds a nominal value of \$1, and the total number of shares equals 190,970,000. Group A and Group B shares are registered shares. Group C shares traded on Borsa İstanbul are bearer shares, whereas other Group C shares are also registered shares. Group A shares hold privileges in electing the Board of Directors, while both Group A and B shares hold privileges in voting at the General Assembly. Excluding independent members, if the Board of Directors is formed of five members, at least two members are to be elected; if the Board of Directors is formed of six or seven members, at least three members are required; if the Board of Directors is formed of eight or nine members, at least four members are required; and if the Board of Directors is formed of ten or eleven members, at least five members are required to be elected from among the candidates nominated by the majority of Group (A) shareholders. Group A shareholders or their proxies have 15 voting rights per share at both Ordinary and Extraordinary General Assembly meetings, while Group B shareholders or their proxies have 10 voting rights per share, and Group C shareholders or their proxies have 1 voting right per share.

As of September 30, 2023, the Group employs 968 personnel. (December 31, 2022: 791 personnel).

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 1- GROUP'S ORGANIZATION AND NATURE OF OPERATIONS (Cont.)

As of September 30, 2023, the Company's distribution of share capital is as stated below:

<u>Shareholders</u>	<u>No. of Shares</u>	<u>Group</u>	<u>Ratio (%)</u>	<u>Amount</u>
Nevin Ulusoy	9.548.501	A	5,00	9.548.501
	2.938.000	B	1,54	2.938.000
	23.589.237	C	12,35	23.589.237
	<b>36.075.738</b>		<b>18,89</b>	<b>36.075.738</b>
Onur Erhan Ulusoy	1.469.000	A	0,77	1.469.000
	3.407.000	B	1,78	3.407.000
	13.024.000	C	6,82	13.024.000
	<b>17.900.000</b>		<b>9,37</b>	<b>17.900.000</b>
Eren Günhan Ulusoy	11.017.499	A	5,77	11.017.499
	8.345.000	B	4,37	8.345.000
	52.380.358	C	27,43	52.380.358
	<b>71.742.857</b>		<b>37,57</b>	<b>71.742.857</b>
Mithat Denizcigil	215.518	C	0,11	215.518
	<b>215.518</b>		<b>0,11</b>	<b>215.518</b>
Kâmil Âdem	60.887	C	0,03	60.887
	<b>60.887</b>		<b>0,03</b>	<b>60.887</b>
Publicly-Traded	<b>64.975.000</b>	C	<b>34,02</b>	<b>64.975.000</b>
<b>Total</b>	<b>190.970.000</b>		<b>100,00</b>	<b>190.970.000</b>

### Subsidiaries

As of December 31, 2022, and September 30, 2023, the Company's subsidiaries are within the scope of consolidation, with their respective direct shareholding percentages detailed below:

<u>Subsidiaries</u>	<u>Shareholding Ratios (%)</u>	
	<u>September 30,</u>	<u>December 31,</u>
	<u>2023</u>	<u>2022</u>
Uludaş Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş.	100	100
Rolweg SA	100	100
Alfaway Gıda Sanayi ve Ticaret A.Ş.	100	100
Söke Değirmencilik Sanayi ve Ticaret A.Ş.	79,95	100
Gen Oyuncak Sanayi ve Ticaret A.Ş. (*)	60	-

(\*) Söke Değirmencilik Sanayi ve Ticaret A.Ş., with the approval of the Board of Directors dated March 29, 2023, acquired the shares of Gen Oyuncak Sanayi ve Ticaret A.Ş. ("Gen Oyuncak") with a nominal value of TL 1.628.400, which corresponds to 60% of the total nominal value of TL 2.714.000 registered shares of Gen Oyuncak Sanayi ve Ticaret A.Ş. ("Gen Oyuncak") for TL 2.862.586 with the Share Transfer Agreement signed between the parties on March 29, 2023.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### **NOTE 1- GROUP'S ORGANIZATION AND NATURE OF OPERATIONS (Cont.)**

#### **Disclosure Regarding the Nature of Activities of Subsidiaries**

##### ***Uludaş Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş.***

Uludaş Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş. ("Uludaş") was founded on February 27, 2015, to engage in licensed warehousing activities for preserving agricultural products in healthy conditions and storing them for commercial purposes within the scope of the license.

Uludaş's headquarters is located at 180-1 Atatürk Boulevard, Şabanoğlu Neighborhood, Tekkeköy, Samsun. Currently, as of September 30, 2023, the company employs 32 personnel. (December 31, 2022: 24 Personnel)

As of December 31, 2022, the Company's capital was increased from TL 27.000.000 to TL 300.000.000 by the resolution of the General Assembly registered on July 11, 2023.

##### ***Rolweg SA***

Rolweg SA was established on March 15, 2018, with a capital of CHF 1,000,000 for trading grain. All the capital of Rolweg is owned by Ulusoy Un Sanayi ve Ticaret A.Ş. The corporate address of Rolweg SA is Rue du Nant6, 1207 Geneva Switzerland. Rolweg SA's share capital, which was CHF 7,500,000 as of December 31, 2021, was increased by CHF 2,500,000 to CHF 10,000,000 with the Board of Directors' resolution dated August 15, 2022. By resolution of the Board of Directors dated August 11, 2023, the share capital was increased by CHF 10,000,000 to CHF 20,000,000.

##### ***Alfaway Gıda Sanayi ve Ticaret A.Ş.***

Alfaway Gıda Sanayi ve Ticaret A.Ş., ("Alfaway") was founded on September 24, 2019 to produce, purchase, sell, and distribute, as well as import and export various types of food items, on a wholesale and retail basis. Alfaway's registered address is Kılıçdede Mahallesi Ülkem Sokak Niş Borkonut İş Merkezi No:8 A-Block Kat:6 Daire:56-57 İlkadım/Samsun.

The capital of TL 5.000.000 as of December 31, 2022 was increased to TL 40.000.000 by the resolution of the General Assembly registered on April 25, 2023. Currently, there are 74 employees as of September 30, 2023. (December 31, 2022: 71 Personnel)

##### ***Söke Değirmencilik Sanayi ve Ticaret A.Ş.***

Söke Değirmencilik was founded in Söke in 1963 and specialized in producing flour. Söke Değirmencilik primarily manufactures flour and related products for the Turkish market. Production is carried out at two locations, with one located in Söke and the other in Ankara. The main location and address of Söke Değirmencilik is at No:2 Sazlı Mahallesi Fabrika Sokak Söke/Aydın. The address of the Ankara Branch of Söke Değirmencilik is Ahi Evranosb Mahallesi Kazakistan Caddesi No:8 Sincan/Ankara.

The shares of Söke Değirmencilik, which were offered to the public trade with a unit price of TL 7.50 on January 4, 5, and 6, 2023, started trading on the Stars Market on January 12, 2023. The registered Board of Directors Decision at the Söke Trade Registry Office on February 8, 2023, increased Söke Değirmencilik's issued capital from TL 309,000,000 to TL 386,500,000. Additionally, 77,500,000 Group B registered shares with a nominal amount of TL 77,500,000 were made publicly available.

As of September 30, 2023, the number of personnel employed is 371. (December 31, 2022:337 Personnel)

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 1- GROUP'S ORGANIZATION AND NATURE OF OPERATIONS (Cont.)**

#### **Disclosure Regarding the Nature of Activities of Subsidiaries (Cont.)**

##### **Gen Oyuncak Sanayi ve Ticaret A.Ş.**

Gen Oyuncak, Gen Proje Yönetimi Mimarlık İnşaat Oyuncak San. ve Tic. Ltd. Şti. was founded on November 1, 2019 to manufacture, purchase, sell, import, and export a variety of toys, including play dough, bouncing dough, modeling dough, painting supplies, pencils, erasers, and office products.

The name of the company Gen Oyuncak has been changed to Gen Oyuncak Sanayi ve Ticaret Anonim Şirketi, following the General Assembly Decision on March 7, 2023, and registration on March 14, 2023.

Gen Oyuncak's headquarters address is Ferhatpaşa Mah. 37. Sk. No:11-13a Ataşehir/İstanbul. As of September 30, 2023, the number of personnel employed is 29 (December 31, 2022: 14 Personnel)

As of September 30, 2023, the share capital is TL 2.714.000. (December 31, 2022: TL 20.000)

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS**

#### **2.1 Basis of Presentation**

The Group presented its consolidated financial statements for the September 30, 2023 interim period in compliance with TAS 34 "Interim Financial Reporting", as well as CMB Communiqué Serial: II, Communiqué No: 14.1, and amendments issued to clarify that communiqué, in accordance with TAS 34 "Interim Financial Reporting According to Article 5 of the Communiqué, the Turkish Financial Reporting Standards (IFRS) published by the Public Oversight Accounting and Auditing Standards Authority (POA) serve as the foundation. IFRSs consist of various standards and interpretations issued by POA under the titles of Turkish Accounting Standards ("TAS"), Turkish Financial Reporting Standards, TAS Interpretations as well as IFRS Interpretations. IFRSs are updated through communiqués to align with the changes in International Financial Reporting Standards ("IFRSs").

The interim financial statements are displayed in the formats stated in the "Announcement on TAS Taxonomy" released by KGK and the Financial Statement Examples and User Guide released by SPK.

On January 20, 2022, KGK released a statement to address concerns regarding whether businesses implementing Turkish Financial Reporting Standards (IFRS) should adopt TAS 29 Financial Reporting in Hyperinflationary Economies for the 2021 fiscal year. Accordingly, it has been noted that entities applying IFRS do not need to make any adjustments under TAS 29 Financial Reporting in Hyperinflationary Economies ("TAS 29"). Subsequently, the KGK has not made any new pronouncements on applying TAS 29. As of the date of these interim consolidated financial statements on September 30, 2023, no adjustment for inflation has been made in accordance with TAS 29 in preparing the interim consolidated financial statements on September 30, 2023.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.1 Basis of Presentation (Cont.)**

##### **Functional and reporting currency**

The Group's consolidated financial statements are presented in TL, which serves as both the functional and presentation currency. The assets and liabilities of the subsidiary operating in foreign countries, as included in the consolidated financial statements prepared in US Dollars, are translated into TL at the balance sheet date's exchange rate, and the income and expenses are translated into TL at the average exchange rate. Exchange rate differences resulting from closing and average exchange rates are recorded in the currency translation reserve within equity.

##### **Netting / Offsetting**

Financial assets and liabilities are offset on the reported balance sheet when there is a legally enforceable right to set off recognized amounts and an intention to settle on a net basis or simultaneously realize the asset and settle the liability. The resulting net amount is reported.

##### **Approval of Consolidated Financial Statements**

The Company Management has approved the interim consolidated financial statements as of September 30, 2023 on November 8, 2023. The General Assembly is authorized to make amendments to the interim consolidated financial statements after issuance.

##### **Basis of Consolidation**

###### **a) Subsidiaries**

The consolidated financial statements include the financial statements of the Company and its subsidiary. The control is provided if the Company meets the following conditions:

- Possess power over the investee company/asset,
- Being open for, or having the right to, variable returns from the investee company/asset,
- Ability to use its authority to have an impact on returns.

In cases where the Company does not have majority voting rights over the investee company/asset, it has control power over the investee company/asset if it has sufficient voting rights to direct/manage the activities of the related investment alone. The Company considers all relevant facts and circumstances in determining whether a majority of the voting power of the relevant investment is sufficient to confer control, including the following factors:

- Comparing the voting right of the company with the voting rights of other shareholders
- Potential voting rights owned by the company and other shareholders;
- Rights arising from other contracts;
- Other events and conditions that may show whether the Company currently has interest in managing the relevant activities (including voting at the general assembly meetings in previous periods) when a decision is required.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

#### 2.1 Basis of Presentation (Cont.)

##### Basis of Consolidation (Cont.)

##### a) Subsidiaries (Cont.)

When a situation or event occurs that may cause a change in at least one of the criteria listed above, the Company reassesses the control over its investment.

Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ends when the Company loses control. Any income and expenses of subsidiaries acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date of acquisition to the date of disposal.

The statements of financial position and statements of profit or loss and other comprehensive income of the Subsidiary are consolidated on a line-by-line basis.

Each element of consolidated profit or loss and other comprehensive income belongs to owners of the parent and non-controlling interests. Total consolidated profit or loss and other comprehensive income of subsidiaries are attributed to the owners of the parent and non-controlling interests, regardless of a reverse balance.

Where necessary, adjustments regarding the accounting policies were made in the financial statements of the subsidiaries to ensure uniformity with the accounting policies followed by the Group.

All intragroup assets and liabilities, equity, income and expenses and cash flows relating to transactions between Group companies are eliminated on consolidation.

The ownership interests of the subsidiaries controlled by the Company as of September 30, 2023 and December 31, 2022 are as follows:

Subsidiaries	Shareholding Ratios (%)	
	September 30, 2023	December 31, 2022
Uludaş Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş.	100	100
Rolweg SA	100	100
Alfaway Gıda Sanayi ve Ticaret A.Ş.	100	100
Söke Değirmencilik Sanayi ve Ticaret A.Ş.	79,95	100
Gen Oyuncak Sanayi ve Ticaret A.Ş.	60	-

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

#### 2.1 Basis of Presentation (Cont.)

##### Basis of Consolidation (Cont.)

##### *b) Affiliates*

Affiliates are accounted for using the equity method. Affiliates are entities in which the Group generally holds between 20% and 50% of the voting rights or has significant influence, but not control, over the operating activities.

Unrealized gains and losses resulting from transactions between the Group and its affiliate are eliminated to the extent of the Group's interest in the affiliate. The equity method is discontinued when the carrying amount of the investment in a affiliate reaches zero or when the Group ceases to have significant influence over the affiliate unless the Group has incurred obligations or made commitments in respect of the affiliate. The carrying amount of the investment at the date that significant influence ceases is subsequently remeasured to fair value if fair value can be measured reliably.

As of September 30, 2023, and December 31, 2022, shares in associates are as follows.

<b>Affiliates</b>	<b>Shareholding Ratios (%)</b>	
	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş. ("Sasbaş")	17	17



## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.2 New and Revised Standards and Commentaries**

##### **a) New standards, amendments, and commentaries to existing standards in force as of September 30, 2023**

###### **Narrow-scope amendments to TAS 1, Implementation Statement 2, and TAS 8**

Valid for annual periods beginning on or after January 1 2023. These amendments are intended to improve accounting policy disclosures and help users of financial statements to distinguish between changes in accounting estimates and differences in accounting policies.

###### **Amendment to TAS 12, Deferred tax on assets and liabilities arising from a single transaction**

Applicable for annual periods beginning on or after January 1 2023. These amendments require companies to recognize deferred tax on transactions that, when first identified in the financial statements, give rise to taxable and deductible temporary differences in equal amounts.

###### **TFRS 17 - The new insurance contract standard**

In February 2019, the POA issued IFRS 17, a comprehensive new accounting standard for insurance contracts covering recognition, measurement, presentation, and disclosure. IFRS 17 introduces a model that measures insurance contract liabilities at their current balance sheet value and recognizes profit over the period the services are provided. IFRS 17 is effective for annual periods beginning on or after January 1 2023. Early adoption is permitted.

###### **Amendment to TAS 12, International tax reform - Pillar two model rules**

Deferred tax exemption and disclosure requirements are enacted. Companies must adhere to these requirements for annual periods beginning on or after January 1 2023. These amendments temporarily exempt affected companies from accounting for deferred taxes resulting from international tax reform by the Organization for Economic Cooperation and Development. Additionally, targeted disclosure requirements are part of these amendments.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.2 New and Revised Standards and Commentaries (Cont.)**

##### **b) As of September 30, 2023, standards and amendments issued but not yet in force**

###### **Classification of liabilities as current and non-current (Amendments to TAS 1)**

In January 2021, POA amended TAS 1 Presentation of Financial Statements. The amendments, effective for annual periods beginning on or after January 1, 2024, clarify the criteria for classifying liabilities as current and non-current. The amendments should be applied retrospectively following TAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors." Early application is permitted.

###### **Amendments to TFRS 16 - Leases on sale and leaseback;**

Effective for annual periods starting on or after January 1, 2024. These revisions add provisions in IFRS 16 for sale and leaseback transactions to clarify how a company accounts for a sale and leaseback after the transaction date. Most likely to be impacted are sale and leaseback deals in which some or all of the lease payments are variable lease payments that do not depend on an index or rate.

###### **Amendments to TAS 7 and IFRS 7 on supplier financing arrangements**

Applicable for fiscal years starting on or after January 1, 2024, these changes necessitate disclosures to boost the clarity of supplier financing arrangements and their effect on a company's debt, cash flow, and exposure to liquidity risk. The disclosure requirements are IMSK's response to investor concerns that certain supplier financing agreements of some companies lack clarity and impede investor analysis.

###### **TSRS 1, "General Requirements for the Disclosure of Sustainability-related Financial Information"**

Effective for annual reporting periods starting on or after January 1, 2024, pending standard approval by local laws or regulations. This standard provides a fundamental framework for disclosing substantial information concerning all sustainable risks and opportunities that a company may encounter.

###### **TSRS 2, "Climate Disclosures"**

Effective for annual reporting periods starting on or after. This is subject to approval by local laws or regulations. This is the first standard to establish disclosure requirements for entities about climate-related risks and opportunities.

###### **TAS 21 Lack of Interchangeability**

Effective for annual periods starting on or after January 1, 2025, an entity will be impacted if it engages in a transaction or activity involving a foreign currency that cannot be converted to another currency on a specific measurement date for a particular purpose. A currency can be exchanged when there is an availability to obtain another currency (with a regular administrative delay). The exchange must occur through a market or clearing mechanism that generates enforceable rights and obligations.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.3 Changes in Accounting Policies**

Changes in accounting policies arising from the first time adoption of a new IFRS are applied in accordance with the transitional provisions of that IFRS, if any, or retrospectively if there are no transitional provisions or if there has been a significant voluntary change in accounting policy, and the prior period consolidated financial statements are restated.

#### **2.4 Changes in accounting estimates and errors**

The effect of a change in an accounting estimate is recognized in the financial statements in the current period in which the change is made if it relates to one period only and prospectively in both the current and future periods if it relates to future periods.

Corrected amounts are recognized retrospectively. An error is corrected by restating the comparative amounts for the prior periods in which it occurred or, if it occurred before the next reporting period, by restating the retained earnings account for that period. If the restatement of the information would result in an excessive expense, the comparative information for prior periods is not restated, but the retained earnings account for the subsequent period is restated for the cumulative effect of the error as at the beginning of that period.

#### **2.5 Comparative Information and Restatement of Prior Period Consolidated Financial Statements**

The accompanying consolidated financial statements are prepared by comparing the consolidated financial position, performance, and cash flows of the Group with those of the previous period to present the trends in the consolidated financial position, performance, and cash flows of the Group. When the presentation or classification of the items in the consolidated financial statements is changed, the prior period consolidated financial statements are reclassified accordingly to maintain comparability, and disclosures are made regarding these matters.

On January 11, 2022, the Company purchased 87,633,475 shares, equal to 100% of the outstanding shares of Söke Değirmencilik Sanayi ve Ticaret A.Ş., for a total consideration of TL 168,900,000 in cash and EUR 650,000 payable on January 11, 2023. In 2023, the Group's management discovered that the consolidated financial statements for the acquisition transaction under the IFRS 3 "Business Combinations" standard failed to recognize the fair values of intangible assets, specifically the "Söke Un" brand value and customer relationships. A valuation report, drafted by PWC Yönetim Danışmanlığı A.Ş. on May 3, 2023, was prepared with respect to the determination of the fair value of the "Söke Un" brand and customer relationships as of the merger date. In accordance with TAS 8 Accounting Policies, Changes in Accounting Estimates and Errors, we have retrospectively corrected errors in our consolidated financial statements regarding the values of our brand and customer relationships based on the valuation report. The following report outlines the effects of this correction on our consolidated financial statements, including the deferred tax effect.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)****2.5 Comparative Information and Restatement of Prior Period Consolidated Financial Statements (Cont.)**

<b>Period</b>	<i>Previously Reported</i>	<b>Adjustment Effects</b>	<i>Revised</i>
	<b>December 31, 2022</b>		<b>December 31, 2022</b>
<b>ASSETS</b>			
<b>Current Assets</b>	<b>7.333.662.376</b>	<b>-</b>	<b>7.333.662.376</b>
Cash and Cash Equivalents	1.519.704.774		1.519.704.774
Financial Investments	1.047.908.349		1.047.908.349
Accounts Receivables	2.946.838.510		2.946.838.510
- <i>Accounts Receivables from Related Parties</i>	<i>101.569.916</i>		<i>101.569.916</i>
- <i>Accounts Receivables from Third Parties</i>	<i>2.845.268.594</i>		<i>2.845.268.594</i>
Other Receivables	57.687.020		57.687.020
- <i>Other Receivables from Related Parties</i>	<i>-</i>		<i>-</i>
- <i>Other Receivables from Third Parties</i>	<i>57.687.020</i>		<i>57.687.020</i>
Derivative Instruments	144.075.641		144.075.641
Inventories	1.283.277.033		1.283.277.033
Prepaid Expenses	214.208.401		214.208.401
Current Period Tax Assets	87.611.727		87.611.727
Other Current Assets	32.350.921		32.350.921
<b>Non-Current Assets</b>	<b>2.782.472.893</b>	<b>500.984.144</b>	<b>3.283.457.037</b>
Accounts Receivables	10.197.097		10.197.097
- <i>Accounts Receivables from Third Parties</i>	<i>10.197.097</i>		<i>10.197.097</i>
Other Receivables	832.953		832.953
- <i>Other Receivables from Third Parties</i>	<i>832.953</i>		<i>832.953</i>
Investments Valued by Equity Method	7.808.666		7.808.666
Investment Properties	968.000		968.000
Right of Use Assets	5.985.770		5.985.770
Tangible Assets	2.420.638.382		2.420.638.382
Intangible Assets	65.074.527	497.104.144	562.178.671
- <i>Goodwill</i>	<i>58.747.694</i>	<i>(15.495.856)</i>	<i>43.251.838</i>
- <i>Other Intangible Assets</i>	<i>6.326.833</i>	<i>512.600.000</i>	<i>518.926.833</i>
Prepaid Expenses	23.502.406		23.502.406
Deferred Tax Income	247.465.092	3.880.000	251.345.092
<b>TOTAL ASSETS</b>	<b>10.116.135.269</b>	<b>500.984.144</b>	<b>10.617.119.413</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)****2.5 Comparative Information and Restatement of Prior Period Consolidated Financial Statements (Cont.)**

Period	Previously Reported December 31, 2022	Adjustment Effects	Revised December 31, 2022
<b>SOURCES</b>			
<b>Short-Term Liabilities</b>	<b>5.972.906.227</b>	<b>-</b>	<b>5.972.906.227</b>
Short-Term Borrowings	1.620.635.261		1.620.635.261
- Bank Loans	1.620.635.261		1.620.635.261
Short-Term Portions of Long-Term Borrowings	772.569.856		772.569.856
Accounts Payables	3.083.354.814		3.083.354.814
- Accounts Payables to Related Parties	4.117.214		4.117.214
- Accounts Payables to Third Parties	3.079.237.600		3.079.237.600
Employee Benefit Obligations	11.158.749		11.158.749
Other Borrowings	205.591.252		205.591.252
- Other Borrowings to Related Parties	205.312.078		205.312.078
- Other Borrowings to Third Parties	279.174		279.174
Derivative Instruments	65.554.675		65.554.675
Deferred Income	100.421.758		100.421.758
Short-Term Provisions	17.333.752		17.333.752
- Short-Term Provisions of Employee Benefit Obligations	3.032.935		3.032.935
- Other Short-Term Provisions	14.300.817		14.300.817
Other Short-Term Liabilities	96.286.110		96.286.110
<b>Long-Term Liabilities</b>	<b>1.328.167.344</b>	<b>106.400.000</b>	<b>1.434.567.344</b>
Long-Term Borrowings	839.994.216		839.994.216
Long-Term Provisions	24.505.736		24.505.736
- Long-Term Provisions of Employee Benefit Obligations	24.505.736		24.505.736
Deferred Tax Liabilities	463.667.392	106.400.000	570.067.392
<b>Equity</b>	<b>2.815.061.698</b>	<b>394.584.144</b>	<b>3.209.645.842</b>
Capital Receipts	190.970.000		190.970.000
Share Repurchased (-)	(64.567.763)		(64.567.763)
Share Premiums (Discounts)	15.269.029		15.269.029
Other Comprehensive Income (Expense) Not to be Reclassified to Profit or Loss	1.574.556.913		1.574.556.913
- Revaluation Increase / (Decrease) on Tangible Assets	1.583.492.480		1.583.492.480
- Defined Benefit Plans Remeasurement Gain	(8.791.736)		(8.791.736)
- Shares of Other Comprehensive Income of Investments Valued by Equity Method Not to be Reclassified to Profit or Loss	(143.831)		(143.831)
Other Accumulated Comprehensive Income (Expense) to be Reclassified to Profit or Loss	144.881.024		144.881.024
- Foreign Currency Translation Adjustments	144.881.024		144.881.024
Nonprofit Restricted Reserves	78.622.024		78.622.024
Retained Earnings	162.445.260		162.445.260
Net Period Profit	712.885.211	394.584.144	1.107.469.355
Equity Attributable to Parent Company	2.815.061.698	394.584.144	3.209.645.840
Non-Controlling Interests	-	-	-
<b>TOTAL SOURCES</b>	<b>10.116.135.269</b>	<b>500.984.144</b>	<b>10.617.119.413</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)****2.5 Comparative Information and Restatement of Prior Period Consolidated Financial Statements (Cont.)**

	<i>Previously Reported</i>	<i>Adjustment Effects</i>	<i>Revised</i>
<b>Type of Financial Statement</b>	<b>Consolidated</b>		<b>Consolidated</b>
<b>Period</b>	<b>January 1- September 30, 2022</b>		<b>January 1- September 30, 2022</b>
Revenue	13.703.582.080	-	13.703.582.080
Cost of Sales	(12.346.539.776)	-	(12.346.539.776)
<b>GROSS PROFIT/LOSS</b>	<b>1.357.042.304</b>	<b>-</b>	<b>1.357.042.304</b>
General Administrative Expenses	(68.907.655)	-	(68.907.655)
Marketing Expenses	(273.279.045)	(14.510.137)	(287.789.182)
Research and Development Expenses	(53.177)	-	(53.177)
Other Income from Operating Activities	1.341.248.255	-	1.341.248.255
Other Loss from Operating Activities	(1.039.845.189)	-	(1.039.845.189)
<b>OPERATING PROFIT/LOSS</b>	<b>1.316.205.493</b>	<b>(14.510.137)</b>	<b>1.301.695.356</b>
Investment Profit	35.663.280	516.504.144	552.167.424
Investment Loss	(2.523.434)	-	(2.523.434)
Impairment Gains (Losses) and Reversals of Impairment Losses Determined under IFRS 9	(2.482.024)	-	(2.482.024)
Share of Profit (Loss) of Investments Valued by Equity Method	2.549.747	-	2.549.747
<b>OPERATING PROFIT/LOSS BEFORE FINANCE EXPENSES</b>	<b>1.349.413.062</b>	<b>501.994.007</b>	<b>1.851.407.069</b>
Finance Profit	816.654.418	-	816.654.418
Finance Loss	(1.430.887.995)	-	(1.430.887.995)
<b>PROFIT/(LOSS) BEFORE TAX FROM CONTINUING OPERATIONS</b>	<b>735.179.485</b>	<b>501.994.007</b>	<b>1.237.173.492</b>
<b>Tax Expenses/Income from Continuing Operations</b>	<b>(55.611.837)</b>	<b>(103.497.972)</b>	<b>(159.109.809)</b>
Current Period Tax Expense / Income	(123.388.029)	-	(123.388.029)
Deferred Tax Expense / Income	67.776.192	(103.497.972)	(35.721.780)
<b>PERIOD PROFIT (LOSS)</b>	<b>679.567.648</b>	<b>398.496.035</b>	<b>1.078.063.683</b>
<b>Distribution of Profit (Loss) for the Period</b>	<b>679.567.648</b>		<b>1.078.063.683</b>
Non-Controlling Interests	-		-
Equity Shares	679.567.648	398.496.035	1.078.063.683

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)****2.5 Comparative Information and Restatement of Prior Period Consolidated Financial Statements (Cont.)**

<b>Type of Financial Statement</b>	<i>Previously Reported</i>	<i>Adjustment</i>	<i>Revised</i>
	<b>Consolidated</b>	<b>Effects</b>	<b>Consolidated</b>
<b>Period</b>	<b>January 1- September 30, 2022</b>		<b>January 1- September 30, 2022</b>
<b>Period Profit</b>	<b>679.567.648</b>	<b>398.496.035</b>	<b>1.078.063.683</b>
<b>Not to Be Reclassified to Profit or Loss</b>	<b>200.892.022</b>	-	<b>200.892.022</b>
Revaluation Increase (Decrease) on Tangible Assets	202.606.603	-	202.606.603
Defined Benefit Plans Remeasurement Gain (Loss)	(1.683.457)	-	(1.683.457)
Other Comprehensive Income of Investments Valued by Equity Method Not to be Reclassified to Profit or Loss	(31.124)	-	(31.124)
<b>Other Comprehensive Income Taxes Not To Be Reclassified To Profit Or Loss</b>	<b>(1.185.129)</b>	-	<b>(1.185.129)</b>
Defined Benefit Plans Remeasurement Gain (Loss), Tax Effect	387.195	-	387.195
Revaluation Increase (Decrease) on Tangible Assets, Tax Effect	(1.579.483)	-	(1.579.483)
Other Comprehensive Income of Associates and Joint Ventures Under Equity Method Not To Be Reclassified to Profit or Loss, Tax Effect	7.159	-	7.159
<b>To Be Reclassified to Profit or Loss</b>	<b>91.597.587</b>	-	<b>91.597.587</b>
Foreign Currency Translation Adjustments	91.597.587	-	91.597.587
<b>Taxes on Other Comprehensive Income to be Reclassified to Profit or Loss</b>	-	-	-
<b>OTHER COMPREHENSIVE INCOME (EXPENSE)</b>	<b>291.304.480</b>	-	<b>291.304.480</b>
<b>TOTAL OTHER COMPREHENSIVE INCOME (EXPENSE)</b>	<b>970.872.128</b>	<b>398.496.035</b>	<b>1.369.368.163</b>
<b>Distribution of Total Other Comprehensive Income</b>	<b>970.872.128</b>	-	<b>1.369.368.163</b>
Non-Controlling Interests	-	-	-
Equity Shares	970.872.128	<b>398.496.035</b>	1.369.368.163

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.6 Summary of Significant Accounting Policies**

##### **Revenue**

Revenue is recognized when goods are delivered, and the amount can be reliably determined. The Group expects to receive economic benefits equal to the fair value of consideration given or received in the transaction. Net sales represent the revenue from goods sold, subtracting returns, discounts, commissions, and sales-related taxes. The Group recognizes revenue based on the following main conditions:

- (a) Identifying customer contracts,
- (b) Determining performance obligations,
- (c) Establishing the transaction price in the agreement,
- (d) Allocating the cost of performance obligations,
- (e) Recognizing revenue upon fulfillment of performance obligations

The Group recognizes revenue from its customers only under the following conditions:

- a) If the parties to the contract have approved the contract (in writing, verbally, or through customary business practices) and have committed to fulfilling their respective obligations as stated in the contract,
- b) If the Group can identify the rights and obligations of both parties regarding the provided product or service,
- c) If the Group can establish payment terms for the provided products and services,
- d) If the contract is of a commercial nature,
- e) If the Group is likely to collect payments for the goods and services it provides to its customers,
- f) When assessing the collectability of the mentioned fees, the company should consider only the customer's ability and willingness to pay as of the due date.

##### **Investment Properties**

Real estate, whether comprising land, buildings, or both, held by an owner or lessee under a finance lease for the primary purpose of generating rental income, capital appreciation, or a combination of both, rather than for utilization in the production or provision of goods or services, administrative functions, or regular business sales, is categorized as investment property.

Investment property is recognized as an asset when it is probable that there will be future economic benefits associated with the property, and the cost of the investment property can be reliably measured. Investment properties are recorded in the consolidated financial statements at their fair value. Any gains or losses resulting from valuation adjustments are recognized in the consolidated statement of profit or loss in the period they occur.

If an impairment review reveals that an investment property's carrying amount exceeds its recoverable amount, the carrying amount is reduced to its recoverable amount. Impairment reviews are conducted for investment properties on a regular basis.



## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

#### 2.6 Summary of Significant Accounting Policies (Cont.)

##### Tangible Assets

The tangible assets held by the Group are carried at their initial cost, with a deduction for accumulated depreciation and impairment losses, which includes any expenses related to preparing the assets for their intended purpose. Land, land improvements, buildings, machinery and equipment, and vehicles are recognized in the consolidated financial statements based on the revaluation model, and the value difference arising from the revaluation of tangible assets is reported under the revaluation reserve in equity and in the statement of comprehensive income of the related period. When disposing of tangible assets, their cost and accumulated depreciation will be deducted from the related accounts, and the resulting gain or loss will be recorded in the income statement. Assets, excluding lands, are subject to depreciation based on the determined rates according to the useful life of the asset.

Costs for replacing or repairing tangible fixed assets may be capitalized if they enhance the asset's future economic benefits. Maintenance expenses fall under this category as well. All other expenses are expensed in the income statement as incurred. If events or changes in circumstances suggest that an impairment loss on an item of tangible assets may have occurred, the carrying amount of the asset is reviewed for possible impairment and, if the carrying amount of the asset exceeds its recoverable amount, the carrying amount is written down to its recoverable amount.

If an item of tangible asset undergoes revaluation and its carrying amount increases, the increase will be directly recognized in equity as a "revaluation reserve" in the consolidated financial statements. Any revaluation increase that reverses a previously expensed revaluation decrease of the same asset is recognized as income to that extent. If an asset's carrying amount decreases due to revaluation, the decrease appears as an expense in the consolidated financial statements. Nonetheless, if a revaluation fund were set up beforehand for said asset, such a decrease would primarily be deducted from the account. Any excess beyond the revaluation fund is shown in the income statement.

The estimated useful lives of tangible assets are as follows:

<b>Type of Tangible Asset</b>	<b>Estimated Useful Years</b>
Land Improvements	25-50 Years
Buildings	25-50 Years
Plant, Machinery and Equipment	4-50 Years
Vehicles	2-15 Years
Fixed Assets	3-50 Years

Depreciation methods, useful lives, and residual values are reviewed at each reporting date and adjusted if necessary.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.6 Summary of Significant Accounting Policies (Cont.)**

##### **Intangible Assets Excluding Goodwill**

###### Computer software and rights

Computer software and rights are recognized at their acquisition cost and amortized on a straight-line basis over their estimated useful lives. They are then carried at cost less accumulated amortization. The estimated useful lives of these assets range between 3 and 15 years.

###### Brands

Separately purchased brands are recorded at their original cost, while brands obtained as part of a business merger are recorded at fair value as of the acquisition date.

As there is no foreseeable limit to the period during which the brands are expected to generate net cash inflows to the Group, the Group has assessed the brands as having an indefinite useful life. Trademarks undergo annual impairment testing or more frequent testing if events or changes in circumstances indicate that the carrying amount may not be recoverable. If impairment exists, the carrying amount of the trademarks is adjusted to its recoverable amount.

###### Customer Relations

Customer relationships obtained through a business combination are acknowledged in the consolidated financial statements at the fair value on the date of acquisition. Customer relationships have limited useful lives and are carried at a cost less the amortization charges. Amortization of customer relationships is computed straight-line over their 15-year estimated useful lives.

##### **Impairment of assets**

Financial assets not recognized in profit or loss are assessed at each reporting date to determine whether there is objective evidence of impairment.

Objective evidence of impairment of financial assets includes the following:

- Default or failure of the debtor to fulfill its obligation;
- Restructuring of an amount subject to conditions that the Group would not consider otherwise;
- The possibility that the borrower or issuer may become bankrupt;
- Negative situations arise in the payment status of these people;
- The disappearance of an active market for a security or
- Observable information that indicates a measurable decrease in the expected cash flows from the financial asset.

A significant or long-term drop in the fair value of an investment in equity securities below cost is also concrete proof of impairment.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.6 Summary of Significant Accounting Policies (Cont.)**

##### **Borrowing costs**

Borrowing costs related to acquiring, constructing, or producing a qualifying long-term asset are capitalized as part of that asset's cost until it's ready for use or sale. However, borrowing costs that are not in this context are expensed during the period in which they were incurred. The Group records all finance costs in the statement of income during the period they are incurred.

##### **Inventories**

Inventories are valued at the lower of their cost or net realizable value, including all costs of purchase and other expenses incurred in bringing the inventories to their current location and condition. Net realizable value refers to the estimated selling price in the ordinary course of business, less the anticipated costs of completion and estimated expenses necessary to facilitate a sale. The weighted average cost method is utilized to determine the inventory value.

##### **Financial Assets**

###### Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, demand deposits, time deposits (deposits maturing in less than three months), and other highly liquid short-term investments that are convertible to a known amount of cash, subject to an insignificant risk of value changes and have a maturity of three months or less from the acquisition date. The Group uses the expected credit loss model to evaluate cash and cash equivalents for impairment.

###### Accounts Receivables

Accounts receivable from the sale of goods to customers are recorded at the original invoice amount and then evaluated at amortized cost using the effective interest rate method. Short-term receivables without a stated interest rate are recorded at the original invoice amount, except when imputing interest has a substantial effect. When there is an indication that the amounts owed will not be collected, the consolidated profit and loss account recognizes an allowance for estimated uncollectible amounts of accounts receivable. The Group applies the expected credit loss model to assess its trade receivables for impairment.

If any or all of the impaired receivable amount is collected following the provision for impairment, the collected amount shall be deducted from the provision and recorded in "Other Operating Income" in the profit and loss statement. Credit finance income or expenses and foreign exchange gains or losses on trade transactions are also recognized in "Other Operating Income/Expenses."

The company engages in factoring to collect some of its receivables. The factoring company assumes the collection risk for certain receivables, for which the related amounts are deducted from the receivable accounts.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.6 Summary of Significant Accounting Policies (Cont.)**

##### **Financial Assets (Cont.)**

###### Derivative Instruments

Derivative instruments are first recognized at acquisition cost, reflecting their fair value at the contract date, and subsequently remeasured at fair value. Any derivative instruments that effectively hedge the Group's risks but do not qualify for hedge accounting are designated as derivatives held for trading. Any changes in fair value are recognized in the income statement.

###### Financial Investments

The Group categorizes its financial investments into two classifications: financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income. The determination of the classification is based on the business model and expected cash flows, which are evaluated based on the intended use of the financial assets. At the acquisition date, Management establishes the classification of its financial assets.

Assets with a business model of collecting contractual cash flows and/or making sales are categorized as fair-value assets through profit or loss. These assets are considered non-current if management doesn't intend to dispose of them within 12 months from the balance sheet date.

The group evaluates any financial asset or liability, excluding trade receivables, at its fair value during the initial recognition stage. Any transaction costs directly associated with obtaining or issuing financial assets and liabilities, other than those at fair value through profit or loss, are either added to or subtracted from the fair value during the initial measurement.

If the fair value of a financial investment at the initial recognition differs from the transaction price, the Group recognizes the difference between the fair value at the initial recognition and the transaction price as a gain or loss if the fair value is based on a valuation technique that uses inputs from observable markets or if the fair value is based on quoted prices for identical assets or liabilities in an active market.

- *Fair value gains or losses recognized on financial assets.*

Consists of financial assets other than those at fair value through other comprehensive income. Financial assets are measured at fair value through profit or loss unless held within a business model to collect contractual cash flows or collect and sell financial assets. The consolidated income statement recognizes gains and losses attributed to asset value changes.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.6 Summary of Significant Accounting Policies (Cont.)**

##### **Financial Assets (Cont.)**

###### Financial Investments (Cont.)

- *Financial assets at fair value through other comprehensive income*

Financial assets at fair value through other comprehensive income comprise "financial investments" in the statement of financial position. The Group assesses the fair value of these assets. Any gains or losses on financial assets, excluding impairment losses and foreign exchange gains or losses, are acknowledged in other comprehensive income. When assets that are held at fair value through other comprehensive income are sold, the valuation difference that was reclassified to other comprehensive income is then moved to retained earnings.

##### **Financial Liabilities**

###### Financial Borrowings

Interest-bearing liabilities are first recognized at fair value and later assessed at fair value through the use of the effective interest rate method.

###### Accounts and Other Payables

Accounts and other payables are initially recognized at fair value and subsequently measured at amortized cost using the effective interest method.

##### **Effects of exchange rate conversion**

In the Group's official records, transactions in foreign currencies (currencies other than the Turkish Lira) are converted to TL using the exchange rates at the transaction date. Assets and liabilities in foreign currencies in the consolidated financial statements are converted to Turkish Lira using the exchange rates as of the reporting date. Foreign exchange gains and losses resulting from the settlement and translation of foreign currency items are acknowledged in the consolidated statement of income.

##### **Earnings / (Loss) per Share**

Earnings per share or loss per share is determined by dividing net profit or loss for the period by the weighted average number of outstanding common shares during the period that are attributable to common shareholders.

In Turkey, businesses can augment their share capital by distributing bonus shares to existing shareholders from retained earnings and by adjusting shareholders' equity for inflation. These bonus shares are deemed issued shares for calculating earnings/(loss) per share. Hence, the weighted average number of shares used to calculate the earnings/(loss) per share is obtained by retroactive effect to the bonus shares.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.6 Summary of Significant Accounting Policies (Cont.)**

##### **Events after the balance sheet date**

Events that occur between the end of the reporting period and the date when the consolidated statement of financial position was authorized for issue. Events after the reporting period are divided into two categories:

- There is new evidence that relevant events existed as of the end of the reporting period (events requiring adjustment after the reporting period); and
- There is evidence that the related events occurred after the reporting period (events that do not require adjustment after the reporting period).

The Group adjusts its consolidated financial statements if there is new evidence that such events existed at the end of the reporting period or if they occurred after the reporting period and require restatement of the financial statements. If such events do not necessitate restatement of the consolidated financial statements, the Group discloses the related matters in the related notes.

##### **Related Parties**

For financial statement purposes, the term "related parties" refers to shareholders of the Group, companies they own, their directors, and other entities known to be associated with them. A related party is any entity that has control over the Group, holds significant influence over the Group due to their interest in it, or is an executive, board member, associate, or general manager of the Group, either directly or indirectly.

##### **Taxation**

Income tax expense comprises current and deferred tax.

##### **(i) Current tax**

Current tax is the expected tax payable or receivable on the taxable profit or loss for the current year and includes any adjustment to tax payable in respect of previous years.

It is calculated using tax rates enacted or substantively enacted at the end of the reporting period. Current tax assets and liabilities can only be offset if certain conditions are met.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.6 Summary of Significant Accounting Policies (Cont.)**

##### **Taxation (Cont.)**

###### ***(ii) Deferred Tax***

Deferred income tax is recognized, using the liability method, for temporary differences that occur between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements.

Deferred tax liabilities are recognized for all taxable temporary differences, while deferred tax assets resulting from deductible temporary differences are recognized only if it is more likely than not that future taxable profit will be available against which the deductible temporary difference can be utilized.

##### **Employee benefit obligations**

###### ***(i) Short-term employee benefit obligations***

Short-term employee benefit obligations are recognized as an expense when the related service is provided. A liability is acknowledged for amounts the Group has a legal or constructive obligation to pay due to the past service of employees and anticipated to be paid when the obligation can be reliably estimated.

###### ***(ii) Other long-term employee benefit obligations***

The severance provision reflects the estimated present value of the probable future obligation of the Group, resulting from employee retirement on a monthly basis. The provision for severance pay accrues as if all employees were to receive payment and is presented in the consolidated financial statements. Provisions for severance indemnity are calculated based on the ceiling announced by the government.

As of September 30, 2023, the maximum amount of severance pay is TL 23.489,83. (December 31, 2022: 19.982,83 TL). The Group management has used certain assumptions in the calculation of provision for employment termination benefits.

All actuarial gains and losses related to severance pay are recognized in other comprehensive income.

##### **Contingent Assets and Liabilities**

TAS 37 "Provisions, Contingent Liabilities, and Contingent Assets" mandates that the Group must have a current legal or constructive obligation arising from past events, with a likelihood that an outflow of resources that embody economic benefits will be necessary to fulfill the obligation, and a trustworthy estimate of the amount of the obligation must be made. If these criteria are not satisfied, the Group must divulge the relevant information in the accompanying notes.

If it is likely that economic benefits will be received in the future, the contingent asset must be disclosed in the consolidated financial statements' notes. Conversely, if it is certain that economic benefits will be received, the asset and its related income are recognized in the consolidated financial statements on the date of the change.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.6 Summary of Significant Accounting Policies (Cont.)**

##### **Business Mergers**

Business acquisitions are recorded utilizing the purchase method of accounting. The consideration exchanged in a business combination is evaluated at fair value. Fair value is then determined by adding together the acquisition-date fair values of the assets transferred by the acquirer, liabilities taken on by the acquirer from the former owners of the acquirer, and equity interests provided by the acquirer. Generally, acquisition costs are recognized as an expense as they are incurred.

Identifiable assets acquired and liabilities assumed are recognized at fair value on the date of acquisition.

However, the following items are not recognized in this manner:

- Deferred tax assets or liabilities, as well as assets or liabilities relating to employee benefits, are accounted for in accordance with the TAS 12 Income Taxes and TAS 19 Employee Benefits standards, respectively.
- Liabilities or equity instruments related to share-based payment arrangements of the acquiree or the Group's share-based payment arrangements replacing those of the acquiree are accounted for following IFRS 2 Share-based Payment during the acquisition date.
- Assets (or disposal groups) that are classified as held for sale in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations are accounted for in accordance with the rules in IFRS 5.

Goodwill is calculated as the excess of the total consideration transferred for the acquisition plus the fair value of any non-controlling interests, if applicable, in the acquiree, and, if the business combination is accomplished in stages, the fair value of any equity interest in the acquiree previously held by the acquirer, minus the net amount of the acquiree's identifiable assets acquired and liabilities assumed as of the acquisition date. If the total amount of the acquiree's identifiable assets and assumed liabilities at the acquisition date is higher than the sum of the fair value of the consideration transferred, non-controlling interests in the acquiree, and the fair value of the acquiree's interest before the acquisition, the excess is recorded as a bargain purchase gain in profit or loss after reassessment.

Non-controlling interests, which entitle shareholders to a proportionate share of the entity's net assets in the event of liquidation, are initially measured at either fair value or at the amount of the acquiree's recognizable net assets that correspond to the non-controlling interests. The determination of the measurement basis is done on a transaction-by-transaction basis. Other non-controlling interests are valued fairly, or, when appropriate, measured using specified methods in a different IFRS.



## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.6 Summary of Significant Accounting Policies (Cont.)**

##### **Business Mergers (Cont.)**

When the Group includes contingent consideration in the consideration transferred in a business combination, it measures the contingent consideration at fair value on the acquisition date and includes it in the said consideration transferred. If the fair value of the contingent consideration requires amendment as a result of more information becoming available during the measurement period, it is adjusted retrospectively against goodwill. The measurement period is the period following the acquisition date in which the acquirer can modify the provisional amounts identified in a business merger. The duration of this period cannot exceed one year from the acquisition date.

The way in which subsequent accounting treats changes in the fair value of contingent consideration that do not qualify as measurement period adjustments depends on the classification of the contingent consideration. If the contingent consideration is classified as equity, it is not remeasured, and any further payments are recognized in equity.

Where purchase accounting for a business merger is incomplete by the end of the reporting period in which the merger took place, the Group reports provisional amounts for items with incomplete accounting. These estimated amounts may be modified during the measurement period or when new information is acquired about facts and circumstances that existed at the time of acquisition, which could impact the recognized amounts at that time.

Certain assets and liabilities of the acquired company that were not previously recognized in its own financial statements are now acknowledged. At the acquisition date, we recognize the identifiable assets, identifiable liabilities, and minority interests of the acquired company at their fair value. The relevant calculations are based on specific assessments and assumptions.

##### **Goodwill**

Goodwill resulting from acquisition is measured at its cost on the date of acquisition, after deduction of any impairment losses, if applicable.

For the sake of impairment testing, goodwill is divided among the cash-generating units (or groups of cash-generating units) of the Group that are expected to gain from the combination's synergies.

The cash-generating unit that receives the goodwill is assessed for impairment annually. If there are any signs that the unit may be damaged, a more frequent impairment test is carried out. If the amount recoverable from the cash-generating unit is lower than its carrying amount, an impairment loss is initially identified for the goodwill assigned to the unit, and then the carrying amount of the assets within the unit is lowered. Any impairment loss for goodwill is directly recognized in the consolidated statement of profit or loss and other comprehensive income. Goodwill impairment cannot be reversed in future periods. When disposing of the appropriate cash-generating unit, the determined goodwill amount is factored into the computation of the gain or loss on disposal.

Sometimes, the acquirer may obtain a bargain purchase, which is a business combination where the net amounts of the assets and liabilities acquired on the acquisition date, measured per IFRSs, exceed the amount paid, typically valued at fair market value, per IFRS regulations. If any surplus amount remains after the application of IFRS 3 - Paragraph 36, the acquirer will acknowledge the resulting gain in profit or loss on the acquisition date, which will be attributed to the acquirer.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### NOTE 2- BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

#### 2.6 Summary of Significant Accounting Policies (Cont.)

##### Goodwill (Cont.)

A bargain purchase might occur during a business merger as a compelled sale where the seller acts under pressure. Nevertheless, acceptance and measurement exclusions for particular items in IFRS 3 - Paragraphs 22-31 may also cause the acceptance of a gain (or a modification in the amount of the recognized profit) in a bargain purchase.

Before recognizing a gain on a bargain purchase, the acquirer reviews whether it has accurately identified the assets acquired and liabilities assumed. Any additional assets or liabilities identified in that assessment are recognized. The acquirer then examines the processes used to measure the amounts of all the following that this IFRS requires to be recognized on the acquisition date:

- (a) Identifiable assets acquired and liabilities assumed;
- (b) Non-controlling interests (minority interests) in the acquiree, if any;
- (c) In a business combination achieved in stages, the acquirer's previously held equity interest in the acquiree and
- (d) Transferred consideration.

The goal of this review is to guarantee that the measurements accurately represent all the information that was available on the acquisition date.

##### Leasing operations

###### Determining whether a contract contains a lease element

Upon contract commencement, the Group assesses if it constitutes a lease or a contract incorporating a lease component. At inception or upon reassessment of the agreement, the Group categorizes the payments due under the contract into payments for lease and payments for other items based on their respective fair values.

If the Group cannot reliably allocate payments under a finance lease, it recognizes an asset and liability equal to the fair value of the related asset. The liability is decreased as subsequent payments are made, and finance expenses added to the liability are recognized using the Group's incremental borrowing rate.

###### Leased assets

Assets held under leases that transfer substantially all the risks and rewards of ownership of the asset to the Group are classified as finance leases. Fixed assets held under finance leases are initially measured at the lower of the asset's fair value and the present value of the minimum lease payments. After initial recognition, they are accounted for according to the accounting policies applicable to the asset.

###### Lease payments

Minimum lease payments made under finance leases are allocated between finance costs and the reduction of the remaining liability. Finance costs are assigned to each lease term period at a predetermined interest rate on the outstanding obligation.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 3 – BUSINESS MERGERS

On March 29, 2023, the Board of Directors approved Söke Değirmencilik's acquisition of 60% of Gen Oyuncak Sanayi ve Ticaret A.Ş.'s registered shares, which have a total nominal value of TL 2,714,000. The acquired shares have a nominal value of TL 1,628,400 and were purchased for a total of TL 2,862,586 through the Share Transfer Agreement between the parties.

In the merger transactions related to the acquisition, Gen Oyuncak's financial statements as of March 31, 2023, are used following the IFRS 3 "Business Combinations" standard since no significant changes occurred after March 29, 2023.

The identifiable assets, liabilities and goodwill arising from the acquisition are as follows:

<b>Identifiable Assets and Liabilities</b>	<b>Fair Value</b>
Cash and Cash Equivalents	863.144
Accounts Receivables	532.198
Other Receivables	2.958.074
Inventories	1.205.116
Other Receivables	5.500
Tangible Assets	281.169
Intangible Assets	1.897
Right of Use Assets	215.124
Deferred Tax Asset	15.606
Short-Term Borrowings	(396.273)
Accounts Payables	(499.710)
Employee Benefit Obligations	(172.170)
Other Short-Term Liabilities	(1.335.269)
Long-Term Borrowings	(146.588)
Long-Term Provisions	(27.787)
<b>Total Identifiable Assets</b>	<b>3.500.031</b>
<b>Acquired Share Ratio</b>	<b>%60</b>
<b>Fair value of the consideration paid for the acquisition of shares</b>	<b>2.862.586</b>
<b>Minus: Total Identifiable Net Assets (60%)</b>	<b>2.100.019</b>
<b>Goodwill</b>	<b>762.567</b>

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 3 – BUSINESS MERGERS (Cont.)

On January 1, 2022, the company acquired 87,633,475 shares, amounting to 100% of Söke Değirmencilik Sanayi ve Ticaret A.Ş.'s share capital. The acquisition was made with TL 168,900,000 in cash and an additional EUR 650,000 payment scheduled for January 1, 2023.

In the merger transactions concerning the acquisition, the financial statements of Söke Değirmencilik Sanayi ve Ticaret A.Ş. as of December 31, 2021, have been utilized under the guidelines of the IFRS 3 standard, "Business Combinations." This approach was taken due to the absence of substantial changes before the January 1, 2022 transaction date.

The identifiable assets and liabilities arising from the acquisition and the calculation of bargain purchase gain are as shown below:

<b>Identifiable Assets and Liabilities</b>	<b>Fair Value</b>
Cash and Cash Equivalents	45.035.333
Accounts Receivables	103.734.344
Other Receivables	10.246.709
Inventories	57.311.187
Prepaid Expenses	25.265.069
Other Current Assets	9.474.382
Other Receivables	9.482
Tangible Assets (*)	116.337.019
Goodwill (**)	43.251.838
Other Intangible Assets (***)	532.271.524
Right of Use Assets	1.827.172
Short-Term Borrowings	(129.643.499)
Accounts Payables	(81.065.284)
Employee Benefit Obligations	(746.011)
Deferred Income	(5.810.074)
Short-Term Provisions	(8.021.650)
Other Short-Term Liabilities	(5.062.945)
Long-Term Borrowings	(750.832)
Long-Term Provisions	(4.035.643)
Deferred Tax Liability	(14.750.524)
<b>Net Identifiable Total Assets</b>	<b>694.877.597</b>
<b>Acquired Share Ratio</b>	<b>100,00%</b>
<b>Fair value of of the consideration paid for the acquisition of shares (****)</b>	<b>178.373.453</b>
<b>Minus: Total Identifiable Net Assets</b>	<b>694.877.597</b>
<b>Bargain Purchase Gain</b>	<b>(516.504.144)</b>

(\*) Tangible assets are the fixed assets owned by Söke Değirmencilik Sanayi ve Ticaret A.Ş. at the time of acquisition, valued by an authorized independent valuation company as per the regulations set by CMB.

(\*\*) TL 43.251.838 of goodwill arises from the purchase accounting calculations made in prior periods in the solo financial statements of Söke Değirmencilik Sanayi ve Ticaret A.Ş..

(\*\*\*) Other intangible assets consist of the fair value of the "Söke Un" brand (TL 241.000.000) and customer relationships (TL 291.000.000) at the date of the merger and the valuation was performed by the independent valuation firm PWC Yönetim Danışmanlığı A.Ş.

(\*\*\*\*) The contingent consideration was paid on January 4, 2023 in accordance with the contract's terms.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 4 – SEGMENT REPORTING**

As of September 30, 2023 and September 30, 2022, the data organized based on reportable segments is presented below:

<b>September 30, 2023</b>	<b>Wheat and Flour Trade</b>	<b>Licensed Warehousing</b>	<b>Elimination</b>	<b>Total</b>
Sales	26.295.387.951	29.247.547	(2.269.949.968)	24.054.685.530
Cost of Sales	(24.975.134.044)	(15.861.076)	2.269.949.968	(22.721.045.152)
<b>Gross Operating Profit</b>	<b>1.320.253.907</b>	<b>13.386.471</b>	-	<b>1.333.640.378</b>
Research and Development Expenses	(519.355)	-	-	(519.355)
General Administrative Expenses (-)	(143.265.015)	(6.180.588)	-	(149.445.603)
Marketing, Sales and Distribution Expenses (-)	(571.401.417)	-	-	(571.401.417)
Other Operating Income	1.853.051.478	1.978.575	(165.713.387)	1.689.316.666
Other Operating Expenses (-)	(991.626.008)	(2.660.126)	-	(994.286.134)
<b>Operating Profit/(Loss)</b>	<b>1.466.493.590</b>	<b>6.524.332</b>	<b>(165.713.387)</b>	<b>1.307.304.535</b>
Income from Investing Activities	428.535.896	-	(27.561.294)	400.974.602
Expenses from Investing Activities	(1.648.422)	-	-	(1.648.422)
Impairment Gains (Losses) and Reversals of Impairment Losses Determined as per IFRS 9	(3.310.221)	-	-	(3.310.221)
Share of Profit / (Loss) of Investments Valued by Equity Method	3.963.862	-	-	3.963.862
<b>Operating Profit / (Loss) Before Finance Expenses</b>	<b>1.894.034.705</b>	<b>6.524.332</b>	<b>(193.274.681)</b>	<b>1.707.284.356</b>
Finance Profit	1.299.117.333	15.250	(41.312.433)	1.257.820.150
Finance Loss (-)	(2.513.521.992)	(15.553.432)	41.312.433	(2,487,762,991)
<b>Profit before Tax</b>	<b>679.630.046</b>	<b>(9.013.850)</b>	<b>(193.274.681)</b>	<b>477.341.515</b>
Tax Expenses	(105.654.176)	(4.173.859)	-	(109.828.035)
<b>Net Period Profit (Loss)</b>	<b>573.975.870</b>	<b>(13.187.709)</b>	<b>(193.274.681)</b>	<b>367.513.480</b>
<b>September 30, 2022</b>	<b>Wheat and Flour Trade</b>	<b>Licensed Warehousing</b>	<b>Elimination</b>	<b>Total</b>
Sales	15.423.195.468	10.808.105	(1.730.421.493)	13.703.582.080
Cost of Sales	(14.069.056.526)	(7.904.743)	1.730.421.493	(12.346.539.776)
<b>Gross Operating Profit</b>	<b>1.354.138.942</b>	<b>2.903.362</b>	-	<b>1.357.042.304</b>
Research and Development Expenses	(53.177)	-	-	(53.177)
General Administrative Expenses (-)	(66.041.135)	(2.866.520)	-	(68.907.655)
Marketing, Sales and Distribution Expenses (-)	(290.942.275)	-	3.153.093	(287.789.182)
Other Operating Income	1.344.406.491	1.162.235	(4.320.471)	1.341.248.255
Other Operating Expenses (-)	(1.035.866.426)	(5.146.141)	1.167.378	(1,039,845,189)
<b>Operating Profit/(Loss)</b>	<b>1.305.642.420</b>	<b>(3.947.064)</b>	-	<b>1.301.695.356</b>
Income from Investing Activities	552.167.424	-	-	552.167.424
Expenses from Investing Activities	(2.523.434)	-	-	(2,523,434)
Impairment Gains (Losses) and Reversals of Impairment Losses Determined as per IFRS 9	(2.482.024)	-	-	(2,482,024)
Share of Profit / (Loss) of Investments Valued by Equity Method	2,549,747	-	-	2,549,747
<b>Operating Profit / (Loss) Before Finance Expenses</b>	<b>1.855.354.133</b>	<b>(3.947.064)</b>	-	<b>1.851.407.069</b>
Finance Profit	842.635.341	16.245	(25.997.168)	816.654.418
Finance Loss (-)	(1,451,298,353)	(5,586,810)	25,997,168	(1,430,887,995)
<b>Profit before Tax</b>	<b>1.246.691.121</b>	<b>(9.517.629)</b>	-	<b>1.237.173.492</b>
Tax Expenses	(159.173.590)	63.781	-	(159,109,809)
<b>Net Period Profit (Loss)</b>	<b>1.087.517.531</b>	<b>(9.453.848)</b>	-	<b>1.078.063.683</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 4 – SEGMENT REPORTING (Cont.)**

<b>September 30, 2023</b>	<b>Wheat and Flour Trade</b>	<b>Licensed Warehousing</b>	<b>Elimination</b>	<b>Total</b>
Total Assets	17.838.596.835	386.085.232	(1.281.007.674)	16.943.674.393
Total Liabilities	13.251.700.325	64.307.201	(461.999.892)	12.854.007.634
Equity Attributable to Parent Company	4.586.896.510	321.778.031	(1.106.569.171)	3.802.105.370
Non-Controlling Interests	-	-	287.561.389	287.561.389

<b>September 30, 2022</b>	<b>Wheat and Flour Trade</b>	<b>Licensed Warehousing</b>	<b>Elimination</b>	<b>Total</b>
Total Assets	10.094.324.048	141.340.142	(1.576.387.940)	8.659.276.250
Total Liabilities	7.541.562.211	72.582.077	(1.014.629.328)	6.599.514.960
Equity Attributable to Parent Company	2.552.761.837	68.758.065	(561.758.612)	2.059.761.290
Non-Controlling Interests	-	-	-	-

<b>September 30, 2023</b>	<b>Wheat and Flour Trade</b>	<b>Licensed Warehousing</b>	<b>Total</b>
Investment Expenditures	629.140.347	79.517.440	708.657.787
Depreciation Expense for the Period	117.545.453	6.737.458	124.282.854

<b>September 30, 2022</b>	<b>Wheat and Flour Trade</b>	<b>Licensed Warehousing</b>	<b>Total</b>
Investment Expenditures	139.181.683	5.791.181	144.972.864
Depreciation Expense for the Period	66.819.497	2.145.739	66.819.497

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 5 – CASH AND CASH EQUIVALENTS

As of September 30, 2023 and December 31, 2022, cash and cash equivalents are as follows:

<b>Cash and Cash Equivalents</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Cash Account	295.740	73.398
Demand Deposits	627.702.668	468.358.504
Time Deposits (*)	984.374.806	1.037.806.360
POS Accounts	3.215.957	14.778.336
Expected Credit Loss	(1.469.249)	(1.311.824)
	<b>1.614.119.922</b>	<b>1.519.704.774</b>

(\*) As of September 30, 2023, the interest rate range for TL Time Deposits is 24-41%. USD Time Deposit Interest Rate is 2%. (December 31, 2022: TL Time Deposits: 15%-23.50% and USD Time Deposits: 1%-3%)

As of September 30, 2023 and December 31, 2022, the details of deposits at banks are as follows:

	<b>September 30, 2023</b>	<b>December 31, 2022</b>
<b>Banks</b>	<b>1.612.077.474</b>	<b>1.506.164.864</b>
Demand Deposit	627.702.668	468.358.504
- TRY Bank	45.397.246	65.267.149
- EURO Bank	9.687.242	3.895.456
- USD Bank	571.367.555	397.707.823
- GBP Bank	18.189	34.418
- CHF Bank	1.232.429	293.287
- JPY Bank	7	-
- RUB Bank	-	1.160.371
Time Deposit	984.374.806	1.037.806.360
- TRY Time Deposit	382.062.654	747.981.861
- USD Time Deposit	602.312.152	289.824.499
	<b>1.612.077.474</b>	<b>1.506.164.864</b>

### NOTE 6 – FINANCIAL INVESTMENTS

As of September 30, 2023 and December 31, 2022, the short-term financial investment information is provided below:

<b>Short-Term Financial Investment</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Bonds	9.905.121	5.925.790
Share Certificates	39.848.167	26.109.576
Blocked Bank Accounts (*)	1.714.143.606	975.586.359
Currency Protected Deposits (**)	9.050.328	40.286.624
	<b>1.772.947.222</b>	<b>1.047.908.349</b>

(\*) Blocked bank deposits were used as collateral for loans. As of September 30, 2023, blocked bank accounts totaling TL 1.559.937.804 comprise currency-hedged deposits. (December 31, 2022: 357.036.526 TL)

(\*\*) TL Time Deposit Account with Currency Protection is a deposit product that protects currency differences if the USD exchange rate increases beyond the interest rate at maturity. Currency-hedged deposit accounts are classified as financial assets held at fair value through profit or loss.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 6 – FINANCIAL INVESTMENTS (Cont.)**

As of September 30, 2023, the value and nominal amount of non-restricted, currency-hedged deposits are detailed below:

Currency	Nominal Amount (Original Currency)	Fair Value (TL Equivalent)	Maturity
USA Dollar	330.000	9.050.328	1.10.2023

As of December 31, 2022, the nominal value and fair value of unhedged deposits in foreign currency are provided below:

Currency	Nominal Amount (Original Currency)	Fair Value (TL Equivalent)	Maturity
USA Dollar	2.000.000	38.352.000	21.08.2023
Euro	100.000	1.934.624	21.08.2023

As of September 30, 2023 and December 31, 2022, the particulars regarding long-term financial investments are as follows:

Long-Term Financial Investments	Share Rate	September 30, 2023	December 31, 2022
Rudi's Organic and Gluten Free Brands Inc.	%12,65	177.711.724	-
		<b>177.711.724</b>	<b>-</b>

Within the scope of Söke Değirmencilik's strategy to expand globally and invest in high-value areas of the food industry that target end consumers, and under the decision made by Söke Değirmencilik's Board of Directors on September 22, 2023, Söke Değirmencilik has decided to acquire 12.65% of Rudi's Organic and Gluten Free Brands Inc. ("Rudi's"), established in 1976 in the US state of Colorado, produces and distributes delicious, organic, gluten-free bread and bakery products with leading food certifications. Rudi's, a producer and distributor of organic, gluten-free bread and bakery products, has agreed with the existing shareholders. After the capital increase, Söke Değirmencilik will pay TL 87,774,600 for 12.65% of Rudi's shares. As of September 30, 2023, TL 28,623,000 of the purchase price has been paid, and the remaining TL 59,151,600 (Note 31) was paid on October 17, 2023.

Regarding the acquisition of Rudi's shares, Note Office Uluslararası Bağımsız Denetim Danışmanlık ve Yeminli Mali Müşavirlik A.Ş. prepared a price determination report on September 14, 2023, which calculated the current market value of Rudi's at USD 51,831,499. In this context, the value of the 12.65% shares owned by Söke Değirmencilik is computed to be \$21,268,000, and the discrepancy of \$4,166,000 between the transaction price of \$20,102,000 and this amount is documented in the statement of profit or loss as investing activity income. (Note 27)



**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 7 – FINANCIAL BORROWINGS**

As of September 30, 2023, and December 31, 2022, the information regarding short-term debt is as follows:

<b>Short-Term Financial Borrowings</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Short-Term Financial Borrowings	4.333.214.794	1.620.635.261
- Bank Loans	4.333.214.794	1.620.635.261
	<b>4.333.214.794</b>	<b>1.620.635.261</b>

As of September 30, 2023, the details of short-term bank borrowings are as follows:

<b>Currency</b>	<b>Interest Rate Range</b>	<b>Foreign Currency Amount</b>	<b>TL Equivalent</b>
USA Dollar	6,25%-10,50%	34.294.455	940.559.721
TL	9,50%-45,50%	-	3.392.655.073
			<b>4.333.214.794</b>

As of December 31, 2022, the details of short-term borrowings are as follows:

<b>Currency</b>	<b>Interest Rate Range</b>	<b>Foreign Currency Amount</b>	<b>TL Equivalent</b>
USA Dollar	7%-9,5%	20.795.339	389.538.292
TL	11,76%-36%	-	1.231.096.969
			<b>1.620.635.261</b>

As of September 30, 2023, and December 31, 2022, the current portion of long-term debt is as follows:

<b>Short-Term Portion of Long-Term Borrowings</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Principal Installments of Long-Term Loans	900.226.551	766.336.251
Borrowings from Lease Transactions	3.264.647	6.233.605
	<b>903.491.198</b>	<b>772.569.856</b>

As of September 30, 2023, the details of the short-term portion of long-term borrowings are as follows:

<b>Currency</b>	<b>Interest Rate Range</b>	<b>Foreign Currency Amount</b>	<b>TL Equivalent</b>
USA Dollar	3,84%-10,94%	14.813.576	406.277.123
TL	3,48%-38,00%	-	493.949.428
			<b>900.226.551</b>

As of December 31, 2022, the details of short-term portion of long-term borrowings are as follows:

<b>Currency</b>	<b>Interest Rate Range</b>	<b>Foreign Currency Amount</b>	<b>TL Equivalent</b>
USA Dollar	7,2%-9,00%	7.758.579	145.333.711
TL	3,84%-26,00%	-	621.002.540
			<b>766.336.251</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 7 – FINANCIAL BORROWINGS (Cont.)**

As of September 30, 2023, the details of short-term lease payables are as follows:

<b>Currency</b>	<b>Foreign Currency Amount</b>	<b>TL Equivalent</b>
USA Dollar	-	-
TL	-	3.264.647
		<b>3.264.647</b>

The details of short-term lease payables as of December 31, 2022 are as follows:

<b>Currency</b>	<b>Foreign Currency Amount</b>	<b>TL Equivalent</b>
USA Dollar	123.117	2.306.228
TL	-	3.927.377
		<b>6.233.605</b>

As of September 30, 2023 and December 31, 2022, the details of long-term borrowings are as follows:

<b>Long-Term Borrowings</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Long-Term Bank Loans	927.357.343	837.236.247
Borrowings from Lease Operations	2.077.223	2.757.969
	<b>929.434.566</b>	<b>839.994.216</b>

As of September 30, 2023, the details of long-term borrowings are as follows:

<b>Currency</b>	<b>Interest Rate Rage</b>	<b>Foreign Currency Amount</b>	<b>TL Equivalent</b>
USA Dollar	3,84%-10,94%	25.939.878	711.427.083
TL	3,48%-38,00%	-	215.930.260
			<b>927.357.343</b>

As of December 31, 2022, the details of long-term bank loans are as follows:

<b>Currency</b>	<b>Interest Rate Rage</b>	<b>Foreign Currency Amount</b>	<b>TL Equivalent</b>
USA Dollar	9,01%	23.239.967	435.331.058
TL	3,48%-26%	-	401.905.189
			<b>837.236.247</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 7 – FINANCIAL BORROWINGS (Cont.)**

As of September 30, 2023, the details of long-term lease payables are as follows:

<b>Currency</b>	<b>Currency Amount</b>	<b>TL Equivalent</b>
TL	-	2.077.223
		<b>2.077.223</b>

As of December 31, 2022, the details of long-term lease payables are as follows:

<b>Currency</b>	<b>Currency Amount</b>	<b>TL Equivalent</b>
TL	-	2.757.969
		<b>2.757.969</b>

As of September 30, 2023, the details of the credits are as follows:

<b>Currency</b>	<b>Foreign Currency Amount</b>	<b>TL Equivalent</b>	<b>Type of Credit</b>
USA Dollar	21.348.364	585.500.224	Spot Credit
USA Dollar	41.884.815	1.148.732.923	Installment Credit
USA Dollar	8.064.644	221.180.931	Rotative
USA Dollar	3.750.086	102.849.849	Participation Banks
TL	-	856.414.221	Rotative
TL	-	695.381.928	Installment Credit
TL	-	1.819.750.000	Spot Loan
TL	-	730.988.612	Participation Banks
	<b>75.047.909</b>	<b>6.160.798.688</b>	

As of December 31, 2022, the details of the credits are as follows:

<b>Currency</b>	<b>Foreign Currency Amount</b>	<b>TL Equivalent</b>	<b>Type of Credit</b>
USA Dollar	5.160.906	96.674.092	Spot Credit
USA Dollar	31.838.917	596.406.599	Usd Installment
USA Dollar	9.750.000	182.637.000	Rotative
TL	-	364.502.485	Rotative
TL	-	659.309.338	Installment Credit
TL	-	649.400.000	Spot Credit
TL	-	675.278.245	Participation Banks
	<b>46.749.823</b>	<b>3.224.207.759</b>	

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 8 – ACCOUNTS RECEIVABLES AND PAYABLES**

As of September 30, 2023 and December 31, 2022, short - term accounts receivable comprised the following:

<b>Short-Term Accounts Receivables</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Accounts Receivables from Related Parties	569.550	101.569.916
Accounts Receivables from Third Parties (*)	5.135.588.388	2.726.957.264
Notes Receivable from Third Parties	274.587.200	152.125.037
Deferred Revenue (-)	(55.347.732)	(33.813.707)
Doubtful Accounts Receivable	21.525.362	13.598.824
Doubtful Accounts Receivable Provisions (-)	(21.525.362)	(13.598.824)
	<b>5.355.397.406</b>	<b>2.946.838.510</b>

(\*) As of December 31, 2022, we have recognized TL 127.569.070 in trade receivables for bread wheat allocations from TMO deliveries. This is in exchange for wheat flour sales to the market at the committed price during October, November, and December 2022 as per the commitment agreement signed with the Turkish Grain Board ("TMO"). (None as of September 30, 2023).

The Group can buy wheat from TMO below market price, in proportion to their sales, by selling flour at a lower price to customers identified within the commitment to TMO. The management of the Group has identified the government incentive benefit as the residual amount resulting from subtracting the revenue determined solely based on the sales price from the overall contract price by the accounting policy modeled after paragraph 10A of TAS 20 *Accounting for Government Grants and Disclosure of Government Assistance Standard*. The benefit received within the scope of the commitment to TMO is recognized as revenue if it does not surpass the stand-alone sales price.

As of September 30, 2023 and December 31, 2022, the movement of doubtful accounts receivables during the period is as follows:

<b>Doubtful Accounts Receivables</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Doubtful Trade Receivables at the Beginning of the Period	13.598.824	6.815.828
Provision Allocated in the Period	7.957.321	8.882.888
Subsidiary Entry	-	1.859.964
Reversed Provision (-)	(30.783)	(3.959.856)
	<b>21.525.362</b>	<b>13.598.824</b>

As of September 30, 2023 and December 31, 2022, long term trade receivables are as follows:

<b>Long-Term Accounts Receivables</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Long-Term Accounts Receivables from Related Parties	-	-
Long-Term Accounts Receivables from Third Parties (*)	10.197.097	10.197.097
	<b>10.197.097</b>	<b>10.197.097</b>

(\*) See Note 19.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 8 – ACCOUNTS RECEIVABLES AND PAYABLES (Cont.)**

As of September 30, 2023 and December 31, 2022, the below list represents short-term accounts payables:

<b>Short-Term Accounts Payables</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Accounts Payables to Related Parties	3.167.544	4.117.214
Accounts Payables to Third Parties (*)	5.569.747.120	3.091.757.326
Notes Payables to Third Parties	22.400.000	4.500.000
Deferred Interest Expense (-)	(15.566.004)	(17.019.726)
	<b>5.579.748.660</b>	<b>3.083.354.814</b>

(\*) As of September 30, 2023, trade payables to third parties are composed of letters of credit in the amount of TL 3,502,339,467 (December 31, 2022: TL 2,110,489,228).

**NOTE 9 – OTHER RECEIVABLES AND PAYABLES**

As of September 30, 2023 and December 31, 2022, the following constituted other short-term receivables:

<b>Other Short-Term Receivables</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Deposits and Collaterals Given	355.859	146.245
Other Receivables from Third Parties	324.610	
Receivables from Public Institutions	103.268.359	57.540.775
Receivables from Employees	28.284	-
	<b>103.977.112</b>	<b>57.687.020</b>

As of September 30, 2023, and December 31, 2022, the following constituted the other long-term receivables from third parties:

<b>Other Long-Term Receivables</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Deposits and Collaterals Given	1.199.458	832.953
	<b>1.199.458</b>	<b>832.953</b>

As of September 30, 2023, and December 31, 2022, the following amounts were recorded as other short-term payables:

<b>Other Short-Term Payables</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Other Payables to Third Parties	1.425.250	279.174
Other Payables to Related Parties	59.151.600	205.312.078
	<b>60.576.850</b>	<b>205.591.252</b>

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 10 – DERIVATIVE INSTRUMENTS

As of September 30, 2023, and December 31, 2022, derivative financial assets are as follows:

<b>Derivative Financial Assets</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Futures Market Collaterals	52.056.730	15.440.035
Derivative Financial Instruments	358.033.763	128.635.606
	<b>410.090.493</b>	<b>144.075.641</b>

As of September 30, 2023 and December 31, 2022, the following represents the derivative financial liabilities:

<b>Derivative Financial Liabilities</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Derivative Financial Instruments	-	65.554.675
	-	<b>65.554.675</b>

(\*) Collateral provided for future trading is categorized as futures market collateral, while the fair values of forward and option contracts are classified as derivative financial instruments. Gains or losses resulting from transactions made during the period appear as income or expenses for derivative financial instruments in the profit and loss statement under financial income and expenses. The fair value differences of open positions as of the reporting date are also included in financial income and expenses.

### Fair Values of Financial Instruments

The Group categorizes its financial instruments carried at fair value in the consolidated financial statements based on the source of the valuation inputs for each type of financial instrument, utilizing a three-tiered hierarchy.

Level 1: Valuation techniques that use quoted prices in active markets for identical assets or liabilities accessible to the Group on the measurement date.

Level 2: Other valuation techniques that utilize inputs other than quoted prices from Level 1, which are observable for either directly or indirectly linked assets or liabilities.

Level 3: Valuation techniques utilize unobservable inputs for assets or liabilities.

<b>September 30, 2023</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Forward Foreign Exchange Contracts (For Trading)	-	410.090.493	-
	-	<b>410.090.493</b>	-
<b>December 31, 2022</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Forward Foreign Exchange Contracts (For Trading)	-	78.520.966	-
	-	<b>78.520.966</b>	-

Foreign currency forward transactions (Level 2) are valued by discounting the fair value of the foreign currency forward contract to the present value using the exchange rate at the balance sheet date.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 11 – INVENTORIES

The details of inventories as of September 30, 2023 and December 31, 2022 are as follows:

<b>Inventories</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Raw Materials and Supplies	881.889.334	500.041.115
Products	340.525.353	196.849.395
Trade Goods	1.620.003.416	387.639.931
Other Inventories	22.588.974	8.572.823
Provision for Impairment of Inventory (-)	(123.378)	(123.378)
Semi-finished Products	177.472.184	190.297.147
	<b>3.042.355.883</b>	<b>1.283.277.033</b>

There are no mortgages, guarantees, or collaterals on inventories, which are insured.

### NOTE 12 – PREPAID EXPENSES AND DEFERRED INCOME

As of September 30, 2023, and December 31, 2022, the particulars of short-term prepaid expenses are below:

<b>Short-Term Prepaid Expenses</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Order Advances Given to Related Parties	6.802.197	9.469.792
Order Advances Given to Third Parties (*)	215.771.896	179.842.753
Insurance and Other Prepaid Expenses	37.999.758	24.895.856
	<b>260.573.851</b>	<b>214.208.401</b>

(\*) Advances refer to the amount advanced to suppliers to purchase raw materials used in production. There is no impairment on the corresponding prepaid expenses as of the end of the period.

The details of long-term prepaid expenses as of September 30, 2023 and December 31, 2022 are as follows:

<b>Long-Term Prepaid Expenses</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Insurance Expenses	26.102.081	20.460.393
Order Advances Given to Third Parties	3.042.014	3.042.013
	<b>29.144.095</b>	<b>23.502.406</b>

As of September 30, 2023 and December 31, 2022, the details of short-term deferred income are as follows:

<b>Short-Term Deferred Income</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Advances Received from Third Parties	126.652.193	100.421.758
Future Months' Income	1.216.350	-
	<b>127.868.543</b>	<b>100.421.758</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 13 – INVESTMENTS VALUED BY EQUITY METHOD**

As of September 30, 2023, and December 31, 2022, the details of investments valued by equity method are as follows:

Name of Affiliate	%	September 30, 2023	%	December 31, 2022
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	17	8.557.673	17	7.808.666

Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	January 1- September 30, 2023	January 1- December 31, 2022
<b>As of January 1</b>	7.808.666	5.316.148
Share of Profit/Loss	3.963.862	3.531.488
Share of Other Comprehensive Income / Expense	(102.365)	(104.897)
Accrued Dividend Income	(3.112.490)	(934.073)
<b>As of the End of the Period</b>	<b>8.557.673</b>	<b>7.808.666</b>

The condensed financial statements of the investment valued by the equity method are as follows:

Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	September 30, 2023	December 31, 2022
Current Assets	21.617.386	23.873.307
Non-current Assets	25.182.132	14.809.392
<b>Total Assets</b>	<b>46.799.518</b>	<b>38.682.699</b>
Short-Term Liabilities	9.359.021	8.665.945
Long-Term Liabilities	7.058.140	4.040.326
Equity	30.382.357	25.976.428
<b>Total Sources</b>	<b>46.799.518</b>	<b>38.682.699</b>

	January 1- September 30, 2023	January 1- September 30, 2022
Sales Income	40.835.850	33.173.795
Net Period Profit/(Loss)	23.316.835	14.998.509

For the fiscal years ending on September 30, 2023, and September 30, 2022, the information regarding the profit or loss share of investments valued under the equity method is presented as follows:

	January 1- September 30, 2023	January 1- September 30, 2022
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	3.963.862	2.549.747
	<b>3.963.862</b>	<b>2.549.747</b>



**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 14 – INVESTMENT PROPERTIES**

The investment property details as of September 30, 2023, and December 31, 2022, are as follows.

<b>Description</b>	<b>January 1, 2023</b>	<b>Inflows</b>	<b>Outflows</b>	<b>Revaluation</b>	<b>September 30, 2023</b>
Land Plots	-	-	-	-	-
Buildings	968.000	-	-	-	968.000
<b>Total Cost Price</b>	<b>968.000</b>	-	-	-	<b>968.000</b>

  

<b>Description</b>	<b>January 1, 2022</b>	<b>Inflows</b>	<b>Outflows</b>	<b>Revaluation</b>	<b>December 31, 2022</b>
Land Plots	9.297.000	-	(9.297.000)	-	-
Buildings	6.995.000	-	(6.719.000)	692.000	968.000
<b>Total Cost Price</b>	<b>16.292.000</b>	-	<b>(16.016.000)</b>	<b>692.000</b>	<b>968.000</b>

Investment properties are reported at fair value. Fair value differences of investment properties are reported under income/expense from investment activities.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 15 – CURRENT TAX ASSETS**

As of December 31, 2022, and September 30, 2023, the following information pertains to assets related to current tax assets:

<b>Current Tax Assets</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Prepaid Taxes and Funds	5.492.236	87.611.727
	<b>5.492.236</b>	<b>87.611.727</b>

**NOTE 16 – RIGHT OF USE ASSETS**

The details of right of use assets as of September 30, 2023 and December 31, 2022 are as follows:

<b>Description</b>	<b>January 1, 2023</b>	<b>Inflows</b>	<b>Outflows</b>	<b>Transfer</b>	<b>Subsidiary Entry</b>	<b>September 30, 2023</b>
Buildings	2.199.095	-	-	-	-	2.199.095
Transportation Vehicles	11.381.260	2.100.745	(964.640)	-	-	12.517.365
Machines	-	-	-	-	291.239	291.239
<b>Total</b>	<b>13.580.355</b>	<b>2.100.745</b>	<b>(964.640)</b>	<b>-</b>	<b>291.239</b>	<b>15.007.699</b>

Buildings	(1.283.098)	(422.169)	-	-	-	(1.705.267)
Transportation Vehicles	(6.311.487)	(3.039.270)	964.640	-	-	(8.386.117)
Machines	-	(69.897)	-	-	(76.115)	(146.012)
<b>Accumulated Depreciation</b>	<b>(7.594.585)</b>	<b>(3.531.336)</b>	<b>964.640</b>	<b>-</b>	<b>(76.115)</b>	<b>(10.237.396)</b>
<b>Net Book Value</b>	<b>5.985.770</b>					<b>4.770.303</b>

<b>Description</b>	<b>January 1, 2022</b>	<b>Inflows</b>	<b>Outflows</b>	<b>Transfer</b>	<b>Subsidiary Entry</b>	<b>December 31, 2022</b>
Buildings	1.505.990	747.474	(54.369)	-	-	2.199.095
Transportation Vehicles	4.179.794	3.719.888	(496.777)	-	3.978.355	11.381.260
<b>Total</b>	<b>5.685.784</b>	<b>4.467.362</b>	<b>(551.146)</b>	<b>-</b>	<b>3.978.355</b>	<b>13.580.355</b>

Buildings	(693.800)	(643.666)	54.368	-	-	(1.283.098)
Transportation Vehicles	(1.334.283)	(3.322.798)	496.777	-	(2.151.183)	(6.311.487)
<b>Accumulated Depreciation</b>	<b>(2.028.083)</b>	<b>(3.966.464)</b>	<b>551.145</b>	<b>-</b>	<b>(2.151.183)</b>	<b>(7.594.585)</b>
<b>Net Book Value</b>	<b>3.657.701</b>					<b>5.985.770</b>

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 17 – TANGIBLE ASSETS

The details of tangible assets as of September 30, 2023 are as follows:

Description	January 1, 2023	Inflows	Outflows	Transfer	Revaluation	Subsidiary Entry	September 30, 2023
Land and Plots	556.354.413	17.437.458	-	-	123.176.413	-	696.968.284
Buildings	502.700.748	39.605.143	-	344.744	60.176.290	-	602.826.925
Land Improvements	27.438.231	4.523.054	-	-	-	-	31.961.285
Facility Machinery and Equipment	1.023.121.002	109.045.654	(719.258)	9.968.672	-	59.025	1.141.475.095
Vehicles	174.067.002	262.043.267	(51.353.066)	-	-	-	384.757.203
Fixtures	17.469.851	12.640.858	(30.918)	101.944	-	161.747	30.343.482
Special Costs	5.891.499	4.180.811	-	-	-	111.661	10.183.971
Ongoing Investments	89.771.549	110.070.899	(2.219.767)	20.387.140	-	-	218.009.821
Advances Given (*)	31.330.007	146.252.096	-	(30.802.500)	-	-	146.779.603
<b>Total Cost Price</b>	<b>2.428.144.302</b>	<b>705.799.240</b>	<b>(54.323.009)</b>	<b>-</b>	<b>183.352.703</b>	<b>332.433</b>	<b>3.263.305.669</b>

  

Accumulated Depreciation	January 1, 2023	Inflows	Outflows	Transfer	Revaluation	Subsidiary Entry	September 30, 2023
Land and Plots	-	-	-	-	-	-	-
Buildings	-	(15.555.991)	-	-	2.691.752	-	(12.864.239)
Land Improvements	(318.614)	(2.147.820)	-	-	-	-	(2.466.434)
Facility Machinery and Equipment	-	(51.700.983)	32.939	-	-	(3.162)	(51.671.206)
Vehicles	-	(32.714.673)	5.056.268	-	-	-	(27.658.405)
Fixtures	(6.404.560)	(2.897.086)	8.506	-	-	(27.060)	(9.320.200)
Special Costs	(782.746)	(512.676)	-	-	-	(21.042)	(1.316.464)
<b>Total</b>	<b>(7.505.920)</b>	<b>(105.529.229)</b>	<b>5.097.713</b>	<b>-</b>	<b>2.691.752</b>	<b>(51.264)</b>	<b>(105.296.948)</b>
<b>Tangible Assets (Net)</b>	<b>2.420.638.382</b>						<b>3.158.008.721</b>

(\*) As of September 30, 2023; TL 118,113,748 consists of advances granted for the Solar Power Plant Project, TL 19,401,630 consists of advances granted within the scope of the Ankara Factory revisions and TL 9,264,225 consists of other advances granted.

As of September 30, 2023, there are bank mortgages on fixed assets in the amount of USD 50,000,000 and TL 12,855,000 (December 31, 2022: USD 50,000,000 and TL 10,175,000).

The Group has carried its tangible assets for which the revaluation model is applied at revalued amounts calculated based on fair values. The difference between these assets' fair value and net book value is added to property, plant, and equipment in assets and to "Revaluation increase (decrease) on tangible assets" in liabilities.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 17 – TANGIBLE ASSETS (Cont.)**

The details of tangible assets as of December 31, 2022 are as follows:

Description	January 1, 2022	Inflows	Outflows	Transfer	Revaluation	Subsidiary Entry	December 31, 2022
Land and Plots	102.458.001	17.423.615	-	-	415.724.797	20.748.000	556.354.413
Buildings	117.732.197	18.475.497	-	2.951.129	338.398.430	25.143.495	502.700.748
Land Improvements	4.805.499	3.751.606	-	173.365	15.995.820	2.711.941	27.438.231
Facility Machinery and Equipment	312.717.633	77.875.406	(2.953.566)	3.061.532	570.318.996	62.101.001	1.023.121.002
Vehicles	15.893.662	79.052.577	(9.024.834)	-	84.540.599	3.604.998	174.067.002
Fixtures	10.134.206	4.894.737	(170.870)	39.259	-	2.572.519	17.469.851
Special Costs	5.699.300	192.199	(9.856.137)	(340.641)	-	10.196.778	5.891.499
Ongoing Investments	37.323.818	58.462.247	(192.501)	(5.884.644)	-	62.629	89.771.549
Advances Given	-	31.330.007	-	-	-	-	31.330.007
<b>Total Cost Price</b>	<b>606.764.316</b>	<b>291.457.891</b>	<b>(22.197.908)</b>	<b>-</b>	<b>1.424.978.642</b>	<b>127.141.361</b>	<b>2.428.144.302</b>

  

Accumulated Depreciation	January 1, 2022	Inflows	Outflows	Transfer	Revaluation	Subsidiary Entry	December 31, 2022
Land and Plots	-	-	-	-	-	-	-
Buildings	(637.277)	(4.668.441)	-	-	5.305.718	-	-
Land Improvements	(214.625)	(760.816)	-	-	656.827	-	(318.614)
Facility Machinery and Equipment	(3.374.906)	(30.638.377)	136.529	-	33.876.754	-	-
Vehicles	(6.971.886)	(8.460.296)	1.077.310	-	14.354.872	-	-
Fixtures	(2.494.098)	(2.458.047)	122.692	-	-	(1.575.107)	(6.404.560)
Special Costs	(186.851)	(595.895)	9.229.235	-	-	(9.229.235)	(782.746)
<b>Total</b>	<b>(13.879.643)</b>	<b>(47.581.872)</b>	<b>10.565.766</b>	<b>-</b>	<b>54.194.171</b>	<b>(10.804.342)</b>	<b>(7.505.920)</b>
<b>Tangible Assets (Net)</b>	<b>592.884.673</b>						<b>2.420.638.382</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 18 – INTANGIBLE ASSETS EXCLUDING GOODWILL**

The details of other intangible assets as of September 30, 2023, are as follows:

<b>Description</b>	<b>January 1, 2023</b>	<b>Inflows</b>	<b>Outflows</b>	<b>Transfer</b>	<b>Subsidiary Entry</b>	<b>September 30, 2023</b>
Customer Relations	291.000.000	-	-	-	-	291.000.000
Brand	241.000.000	-	-	-	-	241.000.000
Copyright (Computer Programs)	4.308.614	1.490.788	-	-	3.250	5.802.652
Other	1.949.830	1.367.759	(93.134)	-	-	3.224.455
Ongoing Investments	2.314.935	-	(455.000)	-	-	1.859.935
<b>Total Cost Price</b>	<b>540.573.379</b>	<b>2.858.547</b>	<b>(548.134)</b>	<b>-</b>	<b>3.250</b>	<b>542.887.042</b>

  

<b>Accumulated Amortization</b>	<b>January 1, 2023</b>	<b>Period Expense</b>	<b>Outflows</b>	<b>Transfer</b>	<b>Subsidiary Entry</b>	<b>September 30, 2023</b>
Customer Relations	(19.400.000)	(14.510.137)	-	-	-	(33.910.137)
Copyright (Computer Programs)	(1.697.065)	(399.057)	221	-	(1.353)	(2.097.254)
Other	(549.481)	(313.095)	-	-	-	(862.576)
<b>Total</b>	<b>(21.646.546)</b>	<b>(15.222.289)</b>	<b>221</b>	<b>-</b>	<b>(1.353)</b>	<b>(36.869.967)</b>
<b>Intangible Assets (Net)</b>	<b>518.926.833</b>					<b>506.017.075</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 18 – INTANGIBLE ASSETS EXCLUDING GOODWILL (Cont.)**

The details of other intangible assets as of December 31, 2022, are as follows:

<b>Description</b>	<b>January 1, 2022</b>	<b>Inflows</b>	<b>Outflows</b>	<b>Transfer</b>	<b>Subsidiary Entry (*)</b>	<b>December 31, 2022</b>
Customer Relations	-	-	-	-	291.000.000	291.000.000
Brand	-	-	-	-	241.000.000	241.000.000
Copyright (Computer Programs)	866.401	2.191.475	-	-	1.250.738	4.308.614
Other	1.639.022	310.808	-	-	-	1.949.830
Ongoing Investments	1.842.130	472.805	-	-	-	2.314.935
<b>Total Cost Price</b>	<b>4.347.553</b>	<b>2.975.088</b>	<b>-</b>	<b>-</b>	<b>533.250.738</b>	<b>540.573.379</b>

  

<b>Accumulated Amortization</b>	<b>January 1, 2022</b>	<b>Period Expense</b>	<b>Outflows</b>	<b>Transfer</b>	<b>Subsidiary Entry</b>	<b>December 31, 2022</b>
Customer Relations	-	-	-	-	(19.400.000)	(19.400.000)
Copyright (Computer Programs)	(469.455)	(248.395)	-	-	(979.215)	(1.697.065)
Other	(290.290)	(259.191)	-	-	-	(549.481)
<b>Total</b>	<b>(759.745)</b>	<b>(507.586)</b>	<b>-</b>	<b>-</b>	<b>(20.379.215)</b>	<b>(21.646.546)</b>
<b>Intangible Assets (Net)</b>	<b>3.587.808</b>					<b>518.926.833</b>

(\*) These entries are related to the acquisition of Söke Değirmencilik shares on January 1, 2022.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 19 – PROVISIONS, CONTINGENT ASSETS AND LIABILITIES

As of September 30, 2023 and December 31, 2022, the details of other short-term provisions are as follows:

<b>Other Short-Term Provisions</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Other Provisions	1.438.673	1.442.647
Contingent Consideration Provision	-	12.858.170
	<b>1.438.673</b>	<b>14.300.817</b>

The Group's receivables from Samsun Yem Sanayi ve Ticaret A.Ş. ("Samsun Yem"), Yemsel Tavukçuluk Hayvancılık Yem Hammaddeleri Sanayi ve Ticaret A.Ş. ("Yemsel"), and Çakıroğlu Gıda Tarım Ürünleri Hayvancılık ve Yem Tavukçuluk Nakliyat Ticaret ve Sanayi A.Ş. ("Çakıroğlu") as of September 30, 2023, and December 31, 2022 are as follows:

<b>Company Title (*)</b>	<b>Accounts Receivable</b>	<b>Order Advances Given</b>	<b>Total</b>	<b>Mortgage Received</b>
Samsun Yem	1.232.128	-	1.232.128	700.000
Yemsel	1.293.727	3.042.014	4.335.741	6.000.000
Çakıroğlu	7.671.242	-	7.671.242	10.000.000
	<b>10.197.097</b>	<b>3.042.014</b>	<b>13.239.111</b>	<b>16.700.000</b>

(\*) Together they will be known as the Çakıroğlu Group.

Samsun Yem, Yemsel, and Çakıroğlu have filed for bankruptcy postponement with the Samsun Commercial Court of First Instance. The Group has established mortgages on the properties of Samsun Yem, Yemsel, and Çakıroğlu for the receivables mentioned above. The mortgages established by the Group allow the collecting of all receivables through the mortgaged properties owned by the Çakıroğlu Group. Samsun Yem and Çakıroğlu are ranked 1st in mortgages. It ranks 2nd in the mortgage on Yemsel's real estate. Akbank T.A.Ş. is ranked 1st in the real estate mortgage of Yemsel. The total mortgage amount of Akbank T.A.Ş. is 6.000.000 TL.

Çakıroğlu Group was notified to pay its debts. On January 8, 2016, an appraisal of the properties was requested. On December 29, 2016, a discovery was made with the Court Committee for Valuation. On January 18, 2017, the experts submitted their reports to the court. The total value of the mortgaged properties belonging to Çakıroğlu was determined to be TL 10,858,440.75. For the mortgaged properties belonging to Yemsel, the total value of TL 11,527,728.25 was appraised. The total value of the mortgaged properties belonging to Samsun Yem was estimated to be 263,249.19 TL. The bankruptcy postponement decision of Samsun Yem Sanayi ve Ticaret A.Ş. was rejected by the Samsun Commercial Court of First Instance on September 30, 2020. The Group requested a revaluation of the real estate. Çakıroğlu and Yemsel were declared bankrupt by the Samsun Commercial Court of First Instance on September 30, 2020.

As of December 31, 2020, the Group had Varlık Taşınmaz Değerleme ve Danışmanlık Şirketi prepare real estate valuation reports as of February 17, 2021 for the mortgaged properties on Çakıroğlu and Samsun Yem properties and the total value of the two properties was determined to be TL 13,364,000. As the fair values of the mortgages and properties in the valuation reports are sufficient to cover the full amount of the receivables, no provision has been made.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 19 – PROVISIONS, CONTINGENT ASSETS AND LIABILITIES (Cont.)**

As of September 30, 2023 and December 31, 2022, the Group's collateral, pledges and mortgages are as follows:

<b>September 30, 2023</b>	<b>TL Equivalent</b>	<b>USA Dollar</b>	<b>Euro</b>	<b>TL</b>
Total amount of CPMs given by its own legal entity and other companies within the scope of consolidation				
- Collateral	266.124.702	4.834.000	2.000.000	75.724.734
-Mortgages	1.381.690.000	50.000.000	-	12.855.000
-Pledges	-	-	-	-
<b>Total</b>	<b>1.647.814.702</b>	<b>54.834.000</b>	<b>2.000.000</b>	<b>88.579.734</b>
<b>December 31, 2022</b>	<b>TL Equivalent</b>	<b>USA Dollar</b>	<b>Euro</b>	<b>TL</b>
Total amount of CPMs given by its own legal entity and other companies within the scope of consolidation				
- Collateral	457.188.465	5.980.600	2.000.000	305.491.612
-Mortgages	945.090.000	50.000.000	-	10.175.000
-Pledges	-	-	-	-
<b>Total</b>	<b>1.402.278.465</b>	<b>55.980.600</b>	<b>2.000.000</b>	<b>315.666.612</b>



## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 20 – EMPLOYEE BENEFIT OBLIGATION PROVISIONS

Under Turkish law, the Group is required to make severance payments to any employee who has completed one year of service and whose employment is terminated without just cause, who is called up for military service, who dies or who retires after completing 25 years of service (20 years for women and 25 years for men) and reaching retirement age (58 years for women and 60 years for men). Due to a change in the law effective September 8, 1999, there are certain transitional obligations regarding the length of service required for retirement.

Such payments are calculated on the basis of 30 days' salary as of September 30, 2023, based on a maximum of the full amount of TL 23,489.83 (December 31, 2022: TL 19,982.83) per year of service at the salary rate applicable at the date of retirement or termination. The provision for severance payments is calculated on a current basis and is reflected in the financial statements. The provision is calculated by estimating the present value of the Group's probable future obligation arising from the retirement of employees. The calculation is based on the maximum retirement age as announced by the government.

The provision for severance pay is calculated by estimating the present value of the future probable obligation of the Group arising from the retirement of the employees. IFRS requires actuarial valuation methods to be used to estimate the Group's obligation under defined benefit plans. Accordingly, the actuarial assumptions used in the calculation of the total liability are set out below.

The basic assumption is that the maximum liability for each year of service will increase in line with inflation. Accordingly, the discount rate used represents the expected real interest rate adjusted for the effects of future inflation. Consequently, in the accompanying consolidated financial statements as of September 30, 2023, the liability is calculated by estimating the present value of the probable future obligation arising from the retirement of the employees. The liability as of September 30, 2023 was calculated using an annual inflation rate of 18.00 percent and an interest rate of 21.00 percent, resulting in a discount rate of approximately 2.54 percent. (The provision at December 31, 2022 was calculated using an annual inflation rate of 18.00 percent and an interest rate of 21.00 percent, resulting in a discount rate of approximately 2.54 percent).

As of September 30, 2023 and December 31, 2022, the Group's accumulated severance liability has changed as follows:

	<b>September 30, 2023</b>	<b>December 31, 2022</b>
<b>January 1 Balance</b>	24.505.736	3.657.593
Current Service Cost	6.736.354	4.681.552
Cost of Interest	6.557.458	5.146.205
Subsidiary Entry	27.787	4.035.643
In Period Payments	(17.820.090)	(2.825.196)
Actuarial Difference	11.246.525	9.809.939
<b>End of Period Balance</b>	<b>31.253.770</b>	<b>24.505.736</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 20 – EMPLOYEE BENEFIT OBLIGATION PROVISIONS (Cont.)**

As of September 30, 2023 and December 31, 2022, short-term provisions for employee benefits are as follows:

<b>Short-term Provisions for Employee Benefits</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Provision for Unused Vacation	6.018.625	3.032.935
	<b>6.018.625</b>	<b>3.032.935</b>

Employee benefit obligations as of September 30, 2023 and December 31, 2022 are as follows:

<b>Employee Benefit Obligations</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Social Security Premiums Payable	9.131.060	3.718.099
Payables to Personnel	19.033.000	7.440.650
	<b>28.164.060</b>	<b>11.158.749</b>

**NOTE 21 – OTHER ASSETS AND LIABILITIES**

As of September 30, 2023 and December 31, 2022, other current assets are as follows:

<b>Other Current Assets</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Carried forward VAT	68.931.988	32.334.907
Personnel Advances	-	3.468
Business Advances	2.561.247	1.677
Other VAT	133.085	10.869
Income Accruals	1.090	-
	<b>71.627.410</b>	<b>32.350.921</b>

As of September 30, 2023 and December 31, 2022, other short-term liabilities are as follows:

<b>Other Short-Term Liabilities</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Taxes and Funds Payable	52.516.300	78.605.280
Expense Accruals	11.730.341	16.912.638
Other Liabilities Payable	45.946	30.000
Overdue, Deferred or Installment Taxes and Other Liabilities	344.043	738.192
	<b>64.636.630</b>	<b>96.286.110</b>

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 22 - EQUITY

#### Capital and Reserves

As of September 30, 2023, the Company's issued share capital amounts to TL 190,970,000 (One hundred ninety million nine hundred and seventy thousand Turkish Liras). (This capital is divided into a total of 190,970,000 shares, 22,035,000 Group A shares, 14,690,000 Group B shares and 154,245,000 Group C shares, each with a nominal value of TL 1.

As of September 30, 2023 and December 31, 2022, the capital structure of the Company is as follows:

Shareholders	Number of Shares	Group	Ratio (%)	Amount
Nevin Ulusoy	9.548.501	A	5,00	9.548.501
	2.938.000	B	1,54	2.938.000
	23.589.237	C	12,35	23.589.237
	<b>36.075.738</b>		<b>18,89</b>	<b>36.075.738</b>
Onur Erhan Ulusoy	1.469.000	A	0,77	1.469.000
	3.407.000	B	1,78	3.407.000
	13.024.000	C	6,82	13.024.000
	<b>17.900.000</b>		<b>9,37</b>	<b>17.900.000</b>
Eren Günhan Ulusoy	11.017.499	A	5,77	11.017.499
	8.345.000	B	4,37	8.345.000
	52.380.358	C	27,43	52.380.358
	<b>71.742.857</b>		<b>37,57</b>	<b>71.742.857</b>
Mithat Denizcigil	215.518	C	0,11	215.518
	<b>215.518</b>		<b>0,11</b>	<b>215.518</b>
Kâmil Âdem	60.887	C	0,03	60.887
	<b>60.887</b>		<b>0,03</b>	<b>60.887</b>
Publicly Traded	<b>64.975.000</b>	C	<b>34,02</b>	<b>64.975.000</b>
<b>Total</b>	<b>190.970.000</b>		<b>100,00</b>	<b>190.970.000</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 22 – EQUITY (Cont.)**

As of December 31, 2022, the Company's capital structure is as follows:

<b>Shareholders</b>	<b>Number of Shares</b>	<b>Group</b>	<b>Ratio (%)</b>	<b>Amount</b>
Nevin Ulusoy	9.548.501	A	5,00	9.548.501
	2.938.000	B	1,54	2.938.000
	23.589.237	C	12,35	23.589.237
	<b>36.075.738</b>		<b>18,89</b>	<b>36.075.738</b>
Onur Erhan Ulusoy	1.469.000	A	0,77	1.469.000
	3.407.000	B	1,78	3.407.000
	13.024.000	C	6,82	13.024.000
	<b>17.900.000</b>		<b>9,37</b>	<b>17.900.000</b>
Eren Günhan Ulusoy	11.017.499	A	5,77	11.017.499
	8.345.000	B	4,37	8.345.000
	52.380.358	C	27,43	52.380.358
	<b>71.742.857</b>		<b>37,57</b>	<b>71.742.857</b>
Mithat Denizcigil	215.518	C	0,11	215.518
	<b>215.518</b>		<b>0,11</b>	<b>215.518</b>
Kâmil Âdem	60.887	C	0,03	60.887
	<b>60.887</b>		<b>0,03</b>	<b>60.887</b>
Publicly Traded	<b>64.975.000</b>	C	<b>34,02</b>	<b>64.975.000</b>
<b>Total</b>	<b>190.970.000</b>		<b>100,00</b>	<b>190.970.000</b>

The legal reserves consist of the first and second legal reserves, established per the Turkish Commercial Code. The first legal reserve is appropriated from the statutory profit at the rate of 5% per year until the total reserve reaches 20% of the company's paid-up share capital.

Publicly traded companies distribute dividends in accordance with the CMB's Communiqué on Dividends No. II-19.1.

Companies distribute profits based on distribution policies determined by the general assembly and in compliance with relevant legislation. The communiqué does not establish a minimum distribution rate. Dividends are distributed according to a company's articles of association or dividend distribution policies. Dividends may be disbursed in equal or varying portions, and dividend payments can be distributed in cash over the earnings noted in the financial statements.

Unless the reserves required by the Turkish Commercial Code and the dividends determined for the shareholders in the Articles of Association or the Dividend Distribution Policy have been set aside, no decision can be taken to set aside other reserves, to carry forward profits to the following year and to distribute dividends to the holders of usufruct shares, members of the Board of Directors, employees of the Company and persons other than shareholders, and no dividend can be distributed to these persons unless the dividends determined for the shareholders are paid in cash.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 22 – EQUITY (Cont.)

The details of equity items as of September 30, 2023 and December 31, 2022 are as follows

Equity	September 30, 2023	December 31, 2022
Paid Capital	190.970.000	190.970.000
Repurchased Shares	(128.911.890)	(64.567.763)
Share Premiums (Discounts)	445.982.390	15.269.029
Other comprehensive income (expense) not to be reclassified to profit or loss	1.560.754.371	1.574.556.913
- Revaluation Differences on Tangible Assets (Net)	1.576.653.012	1.583.492.480
- Actuarial Gain/(Loss) on Employee Benefits	(15.652.446)	(8.791.736)
Shares of Other Comprehensive Income of Investments Valued by Equity Method not to be Reclassified to Profit or Loss	(246.195)	(143.831)
Other Comprehensive Income (Expense) to be Reclassified to Profit or Loss	340.359.560	144.881.024
- Currency Translation Differences	340.359.560	144.881.024
Restricted Reserves	209.113.864	78.622.024
Retained Earnings	878.847.165	162.445.260
Net Profit for the Period	304.989.910	1.107.469.355
Non-controlling Interests	287.561.389	-
	<b>4.089.666.759</b>	<b>3.209.645.842</b>

#### Repurchased Shares

Based on the decision made by the Company's Board of Directors on February 20, 2023, a share repurchase plan started. As part of the present program, shares equivalent to 1.31% of the Company's capital were bought back for TL 64,344,127 between February 24, 2023 and June 14, 2023.

A share buyback plan was started in accordance with the resolution made by the Company's Board of Directors on February 1, 2022. Within the current program, from February 2nd, 2022 to June 30th, 2022, shares with a total nominal value of TL 5,000,000--equivalent to 2.62% of the Company's capital--have been repurchased for TL 37,802,377. As of December 31st, 2021, a share repurchase program had been initiated by the Company's Board of Directors on June 30th, 2021. Within the scope of the current program, from July 1 to December 31, 2021, the Company repurchased shares worth TL 26,765,386 with a nominal value of TL 5,000,000, which is equivalent to 2.62% of its capital.

The Company financed the share repurchases using its cash and cash equivalents. There have been no sales of treasury shares as of September 30, 2023.

Pursuant to Article 520 of Law No. 6102, a reserve has been established for the repurchased shares, equal to their acquisition value. As of September 30, the Group allocated a reserve of TL 128,911,890 for the repurchased shares in the restricted reserves in the consolidated financial statements.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 23 - GOODWILL

Söke Değirmencilik merged with its parent company MKU Un on December 29, 2016. Prior to this merger, on April 16, 2015, MKU Un acquired all of the shares of the Company for TL 103.741.783 and since the acquisition cost includes control power, goodwill amounting to TL 43.251.838 was calculated as a result of this transaction.

Söke Değirmencilik management has performed impairment test on goodwill using discounted cash flow method in accordance with TAS 36. No impairment was identified in the goodwill impairment tests performed by the Company management.

Söke Değirmencilik acquired 60% of the shares of Gen Oyuncak Sanayi ve Ticaret A.Ş. with a total nominal value of TL 2.714.000 for TL 2.862.586 on March 29, 2023. As a result of this transaction, goodwill amounting to TL 762.567 has been calculated.

The details of goodwill as of September 30, 2023 and December 31, 2022 are as follows:

	<b>September 30, 2023</b>	<b>December 31, 2022</b>
<b>As of January 1</b>	43.251.838	43.251.838
Changes in the Period	762.567	-
<b>At the End of the Period</b>	<b>44.014.405</b>	<b>43.251.838</b>
	<b>September 30, 2023</b>	<b>December 31, 2022</b>
MKU Un San. ve Tic. A.Ş.	43.251.838	43.251.838
Gen Oyuncak San. ve Tic. A.Ş.	762.567	-
	<b>44.014.405</b>	<b>43.251.838</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 24 – REVENUE AND COST OF SALES**

Revenue and cost of sales for the periods ended September 30, 2023 and September 30, 2022 are as follows:

<b>Revenue and Cost of Sales</b>	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
Domestic Cost of Sales	6.371.539.348	2.744.213.669	4.567.855.215	1.757.024.411
International Cost of Sales	17.859.978.756	7.544.456.527	9.266.385.040	2.529.168.858
Other Revenue	42.244.805	8.202.654	63.818.296	17.472.876
<b>Gross Sales</b>	<b>24.273.762.909</b>	<b>10.296.872.850</b>	<b>13.898.058.551</b>	<b>4.303.666.145</b>
Returns from Sales (-)	(82.900.344)	(20.891.514)	(98.402.969)	(75.027.788)
Sales Discounts (-)	(134.801.425)	(48.988.736)	(77.871.798)	(29.300.738)
Other Discounts (-)	(1.375.610)	(760.891)	(18.201.704)	(10.094.634)
<b>Net Sales</b>	<b>24.054.685.530</b>	<b>10.226.231.709</b>	<b>13.703.582.080</b>	<b>4.189.242.985</b>
<b>Cost of Sales</b>	<b>(22.721.045.152)</b>	<b>(9.600.576.993)</b>	<b>(12.346.539.776)</b>	<b>(3.862.176.249)</b>
Cost of Trade Goods Sold	(17.237.592.244)	(7.483.815.976)	(8.826.295.261)	(2.514.583.735)
Cost of Finished Goods Sold	(5.447.373.582)	(2.099.460.159)	(3.500.984.030)	(1.340.617.989)
Cost of Service Sold	(34.562.432)	(16.676.261)	(17.138.664)	(6.078.017)
Other Cost of Sales	(1.516.894)	(624.597)	(2.121.821)	(896.508)
<b>Gross Profit/Loss</b>	<b>1.333.640.378</b>	<b>625.654.716</b>	<b>1.357.042.304</b>	<b>327.066.736</b>

Cost of sales for the periods ended September 30, 2023 and September 30, 2022 are as follows:

<b>Cost of Sales</b>	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
<b>Cost of Finished Goods Sold</b>	<b>(5.447.373.582)</b>	<b>(2.099.460.159)</b>	<b>(3.500.984.030)</b>	<b>(1.340.617.989)</b>
<b>Cost of Trade Goods Sold</b>	<b>(17.237.592.244)</b>	<b>(7.483.815.976)</b>	<b>(8.826.295.261)</b>	<b>(2.514.583.735)</b>
<b>Other Cost of Sales</b>	<b>(1.516.894)</b>	<b>(624.597)</b>	<b>(2.121.821)</b>	<b>(896.508)</b>
<b>Cost of Services Sold</b>	<b>(34.562.432)</b>	<b>(16.676.261)</b>	<b>(17.138.664)</b>	<b>(6.078.017)</b>
Amortization Expenses	(14.635.986)	(8.364.939)	(3.932.248)	(578.031)
Vehicle Expenses	(6.586.909)	(2.092.989)	(1.743.578)	(688.377)
Employee Expenses	(4.403.285)	(1.676.738)	(1.699.388)	(646.384)
External Benefits and Services	(3.687.138)	(1.724.028)	(2.588.287)	(1.790.137)
Insurance Expenses	(3.062.332)	(1.494.362)	(931.360)	(285.907)
Other Expenses	(1.227.330)	(807.992)	(1.345.639)	(835.752)
Taxes, Duties and Fees	(431.142)	(265.655)	(119.675)	(33.906)
Maintenance and Repair Expenses	(423.448)	(203.962)	-	-
Transportation Expenses	(104.862)	(45.596)	(4.778.489)	(1.219.523)
	<b>(22.721.045.152)</b>	<b>(9.600.576.993)</b>	<b>(12.346.539.776)</b>	<b>(3.862.176.249)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 25 – GENERAL ADMINISTRATIVE AND MARKETING EXPENSES**

Total operating expenses for the periods ended September 30, 2023 and September 30, 2022 are as follows:

<b>Operating Expenses</b>	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
Marketing Expenses	(571.401.417)	(265.958.039)	(287.789.182)	(107.933.623)
General Administrative Expenses	(149.445.603)	(54.849.757)	(68.907.655)	(23.261.763)
Research and Develop Expenses	(519.355)	(181.150)	(53.177)	(32.335)
	<b>(721.366.375)</b>	<b>(320.988.946)</b>	<b>(356.750.014)</b>	<b>(131.227.721)</b>

For the periods ended September 30, 2023 and September 30, 2022, general administrative expenses are as follows:

<b>General Administrative Expenses</b>	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
Employee Expenses	(63.074.832)	(22.938.626)	(20.566.830)	(7.175.671)
Amortization Expenses	(15.144.039)	(6.337.067)	(6.179.340)	(1.993.003)
External Benefits and Services Expenses	(10.448.878)	(4.741.317)	(10.001.790)	(5.103.291)
Consultancy Expenses	(10.387.943)	(4.700.717)	(6.592.564)	(1.356.159)
Taxes, Duties and Fees	(9.370.102)	(2.378.500)	(3.954.184)	(1.125.139)
Other Expenses	(7.398.228)	(2.737.024)	(4.954.454)	(1.355.736)
Information Processing Expenses	(5.652.350)	(1.953.196)	-	-
Fair Expenses	(3.851.750)	(395.720)	(790.574)	(14.404)
Meal Expenses	(3.584.098)	(1.427.370)	(999.828)	(366.700)
Donations and Aids	(2.995.154)	(571.022)	(960.918)	(20.000)
Lease Expenses	(2.415.596)	(1.471.675)	(2.930.280)	(418.193)
Representation and Hospitality Expenses	(2.205.456)	(803.355)	(1.387.420)	(559.047)
Transportation Expenses	(2.205.314)	(351.132)	(1.194.526)	(844.480)
Vehicle Expenses	(2.147.441)	(1.228.672)	(1.187.947)	(484.069)
Insurance Expenses	(1.744.901)	(676.528)	(1.482.408)	(811.061)
Education and Press Expenses	(1.484.729)	(325.732)	(3.306.085)	(1.054.490)
Electricity, Heating and Water Expenses	(1.181.464)	(360.507)	(806.327)	(268.489)
Accommodation Expenses	(1.141.542)	(1.038.028)	(322.801)	(97.446)
Court and Notary Expenses	(1.055.593)	(135.094)	(254.696)	(14.256)
Maintenance and Repair Expenses	(584.169)	(21.898)	(484.193)	(204.739)
Lease related Amortization Expenses	(565.554)	(94.192)	(174.516)	36.753
Advertisement Expenses	(521.171)	(130.442)	(325.349)	(28.121)
Trademark, Patent Application and Renewal Expenses	(180.296)	(31.943)	(50.625)	(4.022)
Public Offering Expenses	(105.003)	-	-	-
	<b>(149.445.603)</b>	<b>(54.849.757)</b>	<b>(68.907.655)</b>	<b>(23.261.763)</b>



**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 25 – GENERAL ADMINISTRATIVE AND MARKETING EXPENSES (Cont.)**

For the periods ended September 30, 2023 and September 30, 2022, marketing expenses are as follows:

<b>Marketing Expenses</b>	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
Export Expenses	(299.967.362)	(160.527.840)	(141.505.256)	(54.743.235)
Transportation Expenses	(111.132.500)	(42.753.201)	(83.552.227)	(31.563.141)
Employee Expenses	(78.168.528)	(27.314.049)	(29.605.047)	(10.923.905)
Amortization Expenses	(15.546.292)	(8.254.734)	(1.269.728)	(605.842)
Customer Relations Depreciation	(14.510.137)	(4.889.863)	(14.510.137)	(4.889.863)
Vehicle Expenses	(8.447.022)	(4.190.257)	(2.690.901)	(822.969)
Advertising and Promotion Expenses	(8.094.427)	(3.511.344)	-	-
Outsourced Benefits and Services	(6.336.724)	(3.329.100)	(2.928.641)	(1.018.290)
Exchange Expenses	(3.996.844)	(1.073.478)	-	-
Other Miscellaneous Expenses	(3.962.411)	(1.840.811)	(1.341.820)	(74.005)
Fair Expenses	(3.139.152)	(1.269.783)	(1.166.436)	(214.797)
Meal Expenses	(3.025.519)	(1.062.977)	(1.036.918)	(483.905)
Lease related Amortization Expenses	(2.965.781)	(1.063.690)	(1.538.248)	(183.940)
Transportation Expenses	(2.848.162)	(1.543.534)	(666.668)	(143.721)
Accommodation Expenses	(1.672.927)	(480.937)	(254.935)	(36.713)
Rent Expenses	(1.632.651)	(724.988)	(1.623.188)	(965.261)
Taxes, Duties and Fees Expenses	(1.565.863)	(414.984)	(811.442)	(366.866)
Export Expenses	(1.292.325)	(508.631)	(917.517)	(15.584)
Transportation Expenses	(1.278.625)	(557.401)	(516.639)	(116.654)
Employee Expenses	(930.657)	(513.156)	-	-
Amortization Expenses	(834.353)	(100.419)	(1.823.563)	(753.997)
Customer Relations Depreciation	(53.155)	(32.862)	(29.871)	(10.935)
	<b>(571.401.417)</b>	<b>(265.958.039)</b>	<b>(287.789.182)</b>	<b>(107.933.623)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 26 – OTHER OPERATING INCOME AND EXPENSES**

For the periods ended September 30, 2023 and September 30, 2022, other operating income is as follows:

<b>Other Operating Income</b>	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
Foreign Exchange Gains on Accounts Receivable and Payables	1.357.850.237	239.800.158	1.147.227.721	648.901.419
Maturity Difference Income	162.606.542	78.440.663	103.204.595	64.011.737
Rediscount Interest Income	50.781.770	9.051.408	35.938.292	16.159.668
Price Difference Revenues	39.564.645	16.234.540	25.950.336	4.816.028
Service Reflection Revenues	26.860.040	13.755.939	8.921.415	770.335
Provisions for Uncollectible Provisions	25.670.893	3.986.302	6.195.856	982.311
Income from Returned Expenses	12.405.025	6.045.902	6.620.707	1.109.780
Revenues from Law No. 5510 and Law No. 6661	5.185.925	2.015.040	1.922.955	753.318
Other Income	4.988.556	761.453	3.721.012	1.342.790
Income from Incentives and Supports	2.851.352	824.674	1.136.002	450.910
Compensation Income	485.075	140.802	126.898	65.773
Balance Allocation Income	66.606	43.213	268.066	31.283
Licensed Warehouse Rent Support	-	-	14.400	-
	<b>1.689.316.666</b>	<b>371.100.094</b>	<b>1.341.248.255</b>	<b>739.395.352</b>

For the periods ended September 30, 2023 and September 30, 2022, other operating expenses are as follows:

<b>Other Operating Expenses</b>	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
Foreign Exchange Expenses on Accounts Receivable and Payables	(712.525.133)	(117.932.491)	(843.337.633)	(466.228.364)
Price Difference Expenses	(108.751.796)	(5.234.624)	(2.571.318)	(1.689.723)
Maturity Interest Expense	(75.362.790)	(31.779.867)	(141.008.867)	(94.495.204)
Rediscount Interest Expense	(73.769.519)	(14.549.764)	(36.626.947)	(19.146.305)
Reimbursed Expenses	(9.851.422)	(7.877.991)	(6.998.314)	(3.512.605)
Other Expenses	(8.574.918)	(4.079.294)	(5.252.172)	(1.892.877)
Provision Expenses	(5.189.798)	(376.112)	(1.533.322)	(680.000)
Balance Allocation Expenses	(260.758)	(172.799)	(2.516.616)	(100.868)
	<b>(994.286.134)</b>	<b>(182.002.942)</b>	<b>(1.039.845.189)</b>	<b>(587.745.946)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 27 – INCOME AND EXPENSES FROM INVESTING ACTIVITIES**

For the periods ended September 30, 2023 and September 30, 2022, income from investing activities is as follows:

<b>Income from Investing Activities</b>	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
Fair Value Increase of Currency Protected Deposits	302.340.867	181.048.314	29.733.772	20.709.528
Gain on Rudi's Share Purchase (*)	89.937.124	89.937.124	-	-
Income from Sale of Fixed Assets	8.696.611	2.395.141	5.929.508	2.214.110
Gain on Bargain Purchase (Note 3)	-	-	516.504.144	-
	<b>400.974.602</b>	<b>273.380.579</b>	<b>552.167.424</b>	<b>22.923.638</b>

(\*) See Note 6.

For the periods ended September 30, 2023 and September 30, 2022, expenses from investing activities is as follows:

<b>Expenses from Investing Activities</b>	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
Contingent Consideration Valuation Expense	-	-	(2.458.163)	(836.676)
Fixed Asset Sales Expenses	(1.648.422)	(854.516)	(65.271)	(9.232)
	<b>(1.648.422)</b>	<b>(854.516)</b>	<b>(2.523.434)</b>	<b>(845.908)</b>

The details of Impairment Gains (Losses) and Reversals of Impairment Losses determined in accordance with IFRS 9 are as follows:

	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
Expected Credit Loss	(3.310.221)	(1.449.278)	(2.482.024)	(986.991)
	<b>(3.310.221)</b>	<b>(1.449.278)</b>	<b>(2.482.024)</b>	<b>(986.991)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 28 – FINANCIAL INCOME AND EXPENSES**

For the periods ended September 30, 2023 and September 30, 2022, financial income are as follows:

<b>Financial Income</b>	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
Foreign Exchange Gains	455.994.833	27.509.396	491.271.176	121.236.290
Gain on Sale of Marketable Securities	226.272.152	74.813.621	154.997.808	11.287.594
Derivative Financial Instrument Income	374.393.829	40.752.474	130.526.225	1.949.500
Interest Income	201.159.336	9.179.011	39.859.209	18.725.304
	<b>1.257.820.150</b>	<b>152.254.502</b>	<b>816.654.418</b>	<b>153.198.688</b>

For the periods ended September 30, 2023 and September 30, 2022, financial expenses are as follows:

<b>Financial Expenses</b>	<b>January 1- September 30, 2023</b>	<b>July 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>	<b>July 1- September 30, 2022</b>
Foreign Exchange Losses	(1.637.473.902)	(402.977.658)	(727.037.142)	(147.477.072)
Finance Expenses	(626.851.860)	(262.935.844)	(361.891.244)	(181.986.301)
Loss on Sale of Marketable Securities	(155.512.891)	(71.971.276)	(231.296.748)	(24.462.699)
Derivative Financial Instrument Fair Value Differences	(66.856.044)	(2.285.994)	(109.765.363)	(30.302.015)
Finance Expense from Lease Liabilities	(1.068.294)	(371.047)	(897.498)	(373.962)
	<b>(2.487.762.991)</b>	<b>(740.541.819)</b>	<b>(1.430.887.995)</b>	<b>(384.602.049)</b>

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 29 – INCOME TAXES

#### **Corporate Tax**

In Turkey, starting on September 30th, 2023, the corporate tax rate is set at 25%, but until December 31st, 2022, it stands at 23%. The Company's total income is taxable at a rate of 25%, with certain disallowable expenses adjusted, and specific exemptions and allowances deducted.

Turkish tax legislation permits carrying tax losses forward for up to five years to offset future taxable income. However, retained earnings cannot be used to offset tax losses.

There is no practice of reconciling taxes payable with the tax administration in Turkey. Corporate tax returns must be filed within four months after the accounting period's conclusion. Tax authorities can review the tax returns and accounting records for up to five years after the accounting period and may conduct a re-assessment based on their findings.

The Company's subsidiary, Rolweg, operates in Switzerland, where the income tax rate is 12.5%.

#### **Income withholding tax**

As of the Presidential Decree dated 12/21/2021 and numbered 4936, joint stock companies residing in Turkey will now deduct income tax at a rate of 10% instead of the previous rate of 15% on dividend payments made to non-residents of income and corporate taxes, real persons residing in Turkey, and legal entities not residing in Turkey. Dividend payments made by resident joint stock companies in Turkey to other resident joint stock companies are exempt from tax deductions. Additionally, there won't be any tax deductions if the profits are neither distributed nor added to capital.

As of September 30, 2023 and September 30, 2022, total tax income/expense is as follows:

	<b>January 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>
Current Tax Income/Expenses	(75.230.935)	(123.388.029)
Deferred Tax Income/Expenses	(34.597.100)	(35.721.780)
	<b><u>(109.828.035)</u></b>	<b><u>(159.109.809)</u></b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 29 – INCOME TAXES (Cont.)****Deferred tax assets and liabilities**

The Group acknowledges deferred tax assets and liabilities, determined by temporary differences that arise between their financial statements for IFRS purposes and their statutory financial statements. Typically, these differences lead to the recognition of revenue and expenses during different reporting periods for IFRS and tax purposes.

The components of the Group's deferred tax assets and liabilities as of September 30, 2023 are as follows:

<b>September 30, 2023- Deferred Tax Assets</b>	<b>Temporary Differences</b>	<b>Deferred Tax Effect</b>
Tangible and Intangible Assets	809.770.599	171.203.748
Doubtful Receivables	20.120.105	4.977.718
Inventories	13.128.684	3.282.171
Accounts Receivable and Discount on Notes Receivable	95.983.122	20.829.064
Rediscount on Payables and Notes Payable	19.680.217	4.830.560
Derivative Instruments	154.285.807	38.571.452
Exchange Rate Differences	99.924.259	24.077.241
Interest Accruals	248.477.153	62.119.288
Litigation Provisions	1.390.696	347.674
Lease Liability	988.203	247.051
Provision for Unused Vacation Days	4.282.969	1.070.742
Provisions for Severance Pay	43.328.785	10.726.426
Income Accruals	62.228.991	15.557.248
Other Adjustments	34.938.442	8.663.924
	<b>1.608.528.032</b>	<b>366.504.307</b>
<b>September 30, 2023- Deferred Tax Liabilities</b>	<b>Temporary Differences</b>	<b>Deferred Tax Effect</b>
Tangible and Intangible Assets	2.457.496.442	545.399.786
Investment Properties	692.000	129.750
Inventories	26.569.146	6.642.286
Derivative Instruments	184.205.326	46.051.332
Accounts Receivable and Discount on Notes Receivable	43.386.464	9.379.305
Doubtful Receivables	13.246.083	3.311.520
Interest Accruals	380.202.878	95.050.719
Lease Liabilities	2.410.674	602.669
Provision for Unused Vacation Days	2.000.685	500.172
Exchange Rate Differences	117.743.919	28.532.156
Other Adjustments	6.253.441	1.492.670
Income Accruals	62.228.991	15.557.248
Competition Authority Penalty Cancellation	4.953.656	1.238.414
Rediscount on Payables and Notes Payable	18.144.470	3.977.542
Provisions for Severance Pay	30.388.281	7.604.022
Financial Investments	90.762.720	22.690.680
Litigation Provisions	3.974	994
	<b>3.440.689.150</b>	<b>788.161.265</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 29 – INCOME TAXES (Cont.)**

As of December 31, 2022, the Group's deferred tax assets and liabilities are as follows:

<b>December 31, 2022- Deferred Tax Assets</b>	<b>Temporary Differences</b>	<b>Deferred Tax Effect</b>
Doubtful Receivables	12.945.694	3.158.520
Tangible and Intangible Assets (*)	702.248.913	141.432.247
Inventories	13.128.684	3.096.282
Accounts Receivable and Discount on Notes Receivable	42.973.877	8.835.234
Rediscount on Payables and Notes Payable	3.790.421	923.751
Derivative Instruments	154.285.807	35.553.741
Exchange Rate Differences	91.270.215	20.963.861
Interest Accruals	96.613.444	22.880.755
Litigation Provisions	1.411.931	333.244
Lease Liability	125.300	28.819
Provision for Unused Vacation Days	2.090.136	480.731
Provisions for Severance Pay	25.160.641	5.786.947
Other Adjustments	34.764.671	7.870.960
	<b>1.180.809.734</b>	<b>251.345.092</b>

(\*) The Group revalued its depreciable assets by the Tax Procedure Law ("TPL") to recognize a revaluation surplus of TL 621,618,447 in its financial statements. However, the transaction was reversed in its consolidated financial statements prepared under the Reporting Standards, resulting in a deferred tax asset of TL 119,389,901 being recognized.

The group, which currently uses the revaluation model for land, land improvements, plant, machinery, equipment, and vehicles, has reversed the portion of the deferred tax liability calculated under the TAS 12 Income Tax Standard that corresponds to the difference resulting from a decrease in temporary differences calculated for an increase in the value of the aforementioned economic assets by IFRS. Deferred tax totaling TL 103,354,989, resulting from this reversal, is directly recognized in the comprehensive income statement of the consolidated financial statements. Meanwhile, the amount of TL 16,034,912, about non-current assets not following the revaluation model in IFRS, is recorded in the profit and loss statement of the consolidated financial statements.

<b>December 31, 2022- Deferred Tax Liabilities</b>	<b>Temporary Differences</b>	<b>Deferred Tax Effect</b>
Tangible and Intangible Assets	2.298.247.883	449.724.528
Investment Properties	692.000	79.580
Derivative Instruments	87.962.074	21.990.519
Inventories	26.569.146	6.341.168
Accounts Receivable and Discount on Notes Receivable	11.211.180	2.597.312
Doubtful Receivables	13.246.083	3.236.558
Interest Accruals	79.030.250	18.835.791
Lease Liability	1.481.463	341.219
Provision for Unused Vacation Days	2.000.685	460.158
Exchange Rate Differences	112.449.973	25.702.725
Other Adjustments	20.489.165	4.712.701
Competition Authority Penalty Cancellation	5.519.158	1.309.102
Income Accruals	127.569.070	29.340.886
Rediscount on Payables and Notes Payable	3.378.547	745.038
Provisions for Severance Pay	20.216.422	4.650.107
	<b>2.810.063.099</b>	<b>570.067.392</b>

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

As of September 30, 2023 Notes to the Consolidated Financial Statements

(Amounts are in Turkish Lira (TL) unless otherwise indicated.)

### NOTE 30 – EARNINGS PER SHARE

Earnings per share for the periods ended September 30, 2023 and September 30, 2022 are as follows:

	January 1- September 30, 2023	January 1- September 30, 2022
Net Period Profit/Loss	304.989.910	1.078.063.683
Weighted Average Number of Total Ordinary Shares in Circulation	179.678.731	182.321.517
<b>Earnings per Share</b>	<b>1,6974</b>	<b>5,9130</b>

### NOTE 31 – RELATED PARTY DISCLOSURES

For the periods ended September 30, 2023 and December 31, 2022, details of related party disclosures are as follows:

<b>Accounts Receivables from Related Parties</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Unay Un San. ve Tic. A.Ş.	569.550	101.569.916
	<b>569.550</b>	<b>101.569.916</b>

<b>Accounts Payables to Related Parties</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Unay Un San. ve Tic. A.Ş.	2.164.339	3.695.900
Ulusoy Petrol Ürünleri Tic. A.Ş.	643.337	266.419
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	21.493	15.903
Ulusoy Çay Gıda San. ve Tic. A.Ş.	154.687	125.587
GFC Denizcilik ve Ticaret A.Ş.	183.688	13.405
	<b>3.167.544</b>	<b>4.117.214</b>

<b>İlişkili Taraflara Diğer Borçlar</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Unay Un San. ve Tic. A.Ş.	-	205.312.078
Rudi's Organic and Gluten Free Brands Inc. (*)	59.151.600	
	<b>59.151.600</b>	<b>205.312.078</b>

(\*) The payment of the stated amount was completed on October 17, 2023. See Note 6.

<b>Order Advances Given to Related Parties</b>	<b>September 30, 2023</b>	<b>December 31, 2022</b>
Unay Un San. ve Tic. A.Ş.	6.802.197	9.469.792
	<b>6.802.197</b>	<b>9.469.792</b>



**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 31 – RELATED PARTY DISCLOSURES (Cont.)**

For the periods ended September 30, 2023 and September 30, 2022, details of related party disclosures are as follows:

	<b>January 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>
<b>Sales Income from Related Parties</b>		
Unay Un San. ve Tic. A.Ş.	148.964.690	51.601.070
Ulusoy Çay Gıda San. ve Tic. A.Ş.	2.900	-
Eren Günhan Ulusoy	-	2.100
	<b>148.967.590</b>	<b>51.603.170</b>
<b>Purchases from Related Parties</b>		
Ulusoy Çay Gıda San. ve Tic. A.Ş.	154.687	21.068
Unay Un San. ve Tic. A.Ş.	498.640.456	343.283.556
Ulusoy Petrol Ürünleri Tic. A.Ş.	-	112.506
GFC Denizcilik ve Ticaret A.Ş.	34.495	17.204
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	3.126.187	3.928.070
	<b>501.955.825</b>	<b>347.362.404</b>
<b>Other Income from Related Parties</b>		
Unay Un San. ve Tic. A.Ş.	1.641.832	139.974
GFC Denizcilik ve Ticaret A.Ş.	1.715.748	1.640.077
	<b>3.357.580</b>	<b>1.780.051</b>
<b>General Production and Service Expenses to Related Parties</b>		
Unay Un San. ve Tic. A.Ş.	(70.042)	(7.911)
Ulusoy Petrol Ürünleri Tic. A.Ş.	(246.693)	(144.192)
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	(210.071)	(89.428)
	<b>(526.806)</b>	<b>(241.531)</b>
<b>Marketing Expenses to Related Parties</b>		
Unay Un San. ve Tic. A.Ş.	(2.601.445)	(1.551.712)
Ulusoy Petrol Ürünleri Tic. A.Ş.	(2.519.182)	(1.859.490)
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	(616.406)	(63.343)
GFC Denizcilik ve Ticaret A.Ş.	(558.696)	-
	<b>(6.295.729)</b>	<b>(3.474.545)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 31 – RELATED PARTY DISCLOSURES (Cont.)**

For the periods ended September 30, 2023 and September 30, 2022, details of related party disclosures are as follows:

	<b>January 1- September 30, 2023</b>	<b>January 1- September 30, 2022</b>
<b>General Administrative Expenses to Related Parties</b>		
Ulusoy Petrol Ürünleri Tic. A.Ş.	(1.104.092)	(512.714)
Unay Un San. ve Tic. A.Ş.	(62.000)	(23.597)
GFC Denizcilik ve Ticaret A.Ş.	(392)	(13.016)
Ulusoy Çay Gıda San. Ve Tic. A.Ş.	-	(58.190)
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	-	(69.294)
	<b>(1.166.484)</b>	<b>(676.811)</b>
<b>Other Expenses to Related Parties</b>		
Unay Un San. ve Tic. A.Ş.	(64.480)	(136.801)
Ulusoy Petrol Ürünleri Tic. A.Ş.	(4.497)	-
	<b>(68.977)</b>	<b>(136.801)</b>
<b>Financial Expenses from Related Parties</b>		
Unay Un San. ve Tic. A.Ş.	(7.328.807)	(21.861.539)
	<b>(7.328.807)</b>	<b>(21.861.539)</b>
<b>Financial Income from Related Parties</b>		
Unay Un San. ve Tic. A.Ş.	49.441.388	5.800.352
	<b>49.441.388</b>	<b>5.800.352</b>

The executive management of the Group consists of the members of the Board of Directors, the General Manager and the Department Managers. As of September 30, 2023 (December 31, 2022: TL 16.943.872), the Group provided remuneration and benefits amounting to TL 28,663,336 to its executive management personnel.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 32 – NATURE AND LEVEL OF RISKS ARISING FROM FINANCIAL INSTRUMENTS****Credit Risk**

September 30, 2023	Receivables				Bank Deposits	Derivative Instruments	Other
	Accounts Receivables		Other Receivables				
	Related Parties	Third Parties	Related Parties	Third Parties			
<b>Maximum credit risk as of the reporting date (A+B+C+D+E+F)</b>	<b>569.550</b>	<b>5.365.024.953</b>	-	<b>105.176.570</b>	<b>1.612.077.474</b>	<b>410.090.493</b>	<b>2.042.448</b>
- The part of maximum risk secured by collaterals etc.	-	-	-	-	-	-	-
<b>A.</b> Net book value of financial assets that are neither past due nor impaired	569.550	5.368.335.174	-	105.176.570	1.612.077.474	410.090.493	2.042.448
<b>B.</b> Carrying amount of financial assets with renegotiated terms that would otherwise be considered past due or impaired	-	-	-	-	-	-	-
<b>C.</b> Net book value of assets past due but not impaired	-	-	-	-	-	-	-
- Portion secured with collateral etc.	-	-	-	-	-	-	-
<b>D.</b> Net book value of impaired assets	-	-	-	-	-	-	-
- Past due (gross book value)	-	-	-	-	-	-	-
- Impairment (-)	-	-	-	-	-	-	-
- Not past due (gross book value)	-	21.525.362	-	-	-	-	-
- Impairment (-)	-	(21.525.362)	-	-	-	-	-
<b>E.</b> Off-balance sheet items with loans	-	-	-	-	-	-	-
<b>F.</b> Expected Credit Loss	-	(3.310.221)	-	-	-	-	-

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 32 – NATURE AND LEVEL OF RISKS ARISING FROM FINANCIAL INSTRUMENTS (Cont.)****Credit Risk (Cont.)**

December 31, 2022	Receivables				Bank Deposits	Derivative Instruments	Other
	Accounts Receivables		Other Receivables				
	Related Parties	Third Parties	Related Parties	Third Parties			
<b>Maximum credit risk as of the reporting date (A+B+C+D+E+F)</b>	<b>101.569.916</b>	<b>2.855.465.691</b>	-	<b>58.519.973</b>	<b>1.506.164.864</b>	<b>144.075.641</b>	<b>13.539.910</b>
- The part of maximum risk secured by collaterals etc.	-	-	-	-	-	-	-
<b>A.</b> Net book value of financial assets that are neither past due nor impaired	101.569.916	2.858.698.636	-	58.519.973	1.506.164.864	144.075.641	13.539.910
<b>B.</b> Carrying amount of financial assets with renegotiated terms that would otherwise be considered past due or impaired	-	-	-	-	-	-	-
<b>C.</b> Net book value of assets past due but not impaired	-	-	-	-	-	-	-
- Portion secured with collateral etc.	-	-	-	-	-	-	-
<b>D.</b> Net book value of impaired assets	-	-	-	-	-	-	-
- Past due (gross book value)	-	-	-	-	-	-	-
- Impairment (-)	-	-	-	-	-	-	-
- Not past due (gross book value)	-	13.598.824	-	-	-	-	-
- Impairment (-)	-	(13.598.824)	-	-	-	-	-
<b>E.</b> Off-balance sheet items with loans	-	-	-	-	-	-	-
<b>F.</b> Expected Credit Loss	-	(3.232.945)	-	-	-	-	-

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 32 – NATURE AND LEVEL OF RISKS ARISING FROM FINANCIAL INSTRUMENTS (Cont.)****Liquidity risk**

<b>September 30, 2023</b>						
<b>Non-Derivative Financial Liabilities</b>	<b>Book Value</b>	<b>Total cash outflows per contract (I+II+III+IV)</b>	<b>Less than 3 months (I)</b>	<b>3-12 Monts (II)</b>	<b>1-5 Years (III)</b>	<b>More than 5 Years (IV)</b>
Bank Loans	6.166.140.558	6.166.140.558	2.323.140.756	2.913.565.236	926.629.867	2.804.699
Accounts Payables	5.579.748.660	5.579.748.660	2.432.339.684	3.147.408.976	-	-
Other Payables	60.576.850	60.576.850	60.576.850	-	-	-
<b>Total Liabilities</b>	<b>11.806.466.068</b>	<b>11.806.466.068</b>	<b>4.816.057.290</b>	<b>6.060.974.212</b>	<b>926.629.867</b>	<b>2.804.699</b>

<b>December 31, 2022</b>						
<b>Non-Derivative Financial Liabilities</b>	<b>Book Value</b>	<b>Total cash outflows per contract (I+II+III+IV)</b>	<b>Less than 3 months (I)</b>	<b>3-12 Monts (II)</b>	<b>1-5 Years (III)</b>	<b>More than 5 Years (IV)</b>
Bank Loans	3.233.199.333	3.233.199.333	711.118.923	1.682.086.194	835.526.785	4.467.431
Accounts Payables	3.083.354.814	3.083.354.814	1.590.177.450	1.493.177.364	-	-
Other Payables	205.591.252	205.591.252	205.591.252	-	-	-
<b>Total Liabilities</b>	<b>6.522.145.399</b>	<b>6.522.145.399</b>	<b>2.506.887.625</b>	<b>3.175.263.558</b>	<b>835.526.785</b>	<b>4.467.431</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 32 – NATURE AND LEVEL OF RISKS ARISING FROM FINANCIAL INSTRUMENTS (Cont.)****Exchange Rate Risk**

	<b>September 30, 2023</b>			
	<b>TL Equivalent</b>	<b>USA Dollar</b>	<b>Euro</b>	<b>Other</b>
1. Accounts receivables	4.017.944.488	146.174.413	557.050	-
2a. Monetary financial assets (including cash and bank accounts)	1.280.465.700	46.372.566	333.692	41.647
2b. Non-monetary financial assets	-	-	-	-
3. Other	298.080.311	10.888.102	-	-
<b>4. Current Assets (1+2+3)</b>	<b>5.596.490.499</b>	<b>203.435.082</b>	<b>890.741</b>	<b>41.647</b>
5. Accounts receivables	-	-	-	-
6a. Monetary financial assets	-	-	-	-
6b. Non-monetary financial assets	-	-	-	-
7. Other	-	-	-	-
<b>8. Non-current Assets (5+6+7)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>9. Total Assets (4+8)</b>	<b>5.596.490.499</b>	<b>203.435.082</b>	<b>890.741</b>	<b>41.647</b>
10. Accounts payables	5.093.155.433	185.021.181	645.210	-
11. Financial liabilities	1.346.836.844	49.108.030	-	-
12a. Other monetary financial liabilities	-	-	-	-
12b. Other non-monetary financial liabilities	-	-	-	-
<b>13. Short-term liabilities (10+11+12)</b>	<b>6.439.992.278</b>	<b>234.129.212</b>	<b>645.210</b>	<b>-</b>
14. Accounts payables	-	-	-	-
15. Financial liabilities	711.427.083	25.939.878	-	-
16 a. Other monetary financial liabilities	-	-	-	-
16 b. Other non-monetary financial liabilities	-	-	-	-
<b>17. Long term liabilities (14+15+16)</b>	<b>711.427.083</b>	<b>25.939.878</b>	<b>-</b>	<b>-</b>
<b>18. Total liabilities (13+17)</b>	<b>7.151.419.361</b>	<b>260.069.089</b>	<b>645.210</b>	<b>-</b>
19. Net asset/(liability) position of off-balance sheet derivative instruments (19a-19b)	49.082.084	1.792.842	-	-
19a. Total amount of hedged assets	49.082.084	1.792.842	-	-
19b. Total amount of hedged liabilities	-	-	-	-
<b>20. Net foreign currency asset/(liability) position (9-18+19)</b>	<b>(1.505.846.777)</b>	<b>(54.841.166)</b>	<b>245.531</b>	<b>41.647</b>
21. Total fair value of financial instruments used for foreign currency hedges (1 +2a+3+5+6a+7-10-11 -12a-14-15-16a)	<b>(1.554.928.862)</b>	<b>(56.634.007)</b>	<b>245.531</b>	<b>41.647</b>
21. Export(Average Exchange Rate)	<b>2.315.254.693</b>	<b>102.734.841</b>	<b>1.712.987</b>	<b>-</b>
21. Import (Average Exchange Rate)	<b>2.723.776.343</b>	<b>55.588.374</b>	<b>4.825.333</b>	<b>-</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 32 – NATURE AND LEVEL OF RISKS ARISING FROM FINANCIAL INSTRUMENTS (Cont.)****Exchange Rate Risk**

		<b>December 31, 2022</b>			
		<b>TL Equivalent</b>	<b>USA Dollar</b>	<b>Euro</b>	<b>Other</b>
1.	Accounts receivables	1.028.917.322	54.349.482	28.014	46.632.515
2a.	Monetary financial assets (including cash and bank accounts)	789.864.296	41.954.657	195.409	4.487.957
2b.	Non-monetary financial assets	-	-	-	-
3.	Other	28.696.675	1.534.721	-	-
<b>4.</b>	<b>Current Assets (1+2+3)</b>	<b>1.847.478.293</b>	<b>97.838.860</b>	<b>223.423</b>	<b>51.120.472</b>
5.	Accounts receivables	-	-	-	-
6a.	Monetary financial assets	-	-	-	-
6b.	Non-monetary financial assets	-	-	-	-
7.	Other	-	-	-	-
<b>8.</b>	<b>Non-current Assets (5+6+7)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>9.</b>	<b>Total Assets (4+8)</b>	<b>1.847.478.293</b>	<b>97.838.860</b>	<b>223.423</b>	<b>51.120.472</b>
10.	Accounts payables	2.554.342.331	135.902.048	431.889	-
11.	Financial liabilities	537.178.231	28.677.036	-	-
12a.	Other monetary financial liabilities	-	-	-	-
12b.	Other non-monetary financial liabilities	-	-	-	-
<b>13.</b>	<b>Short-term liabilities (10+11+12)</b>	<b>3.091.520.562</b>	<b>164.579.084</b>	<b>431.889</b>	<b>-</b>
14.	Accounts payables	-	-	-	-
15.	Financial liabilities	435.331.056	23.239.967	-	-
16 a.	Other monetary financial liabilities	-	-	-	-
16 b.	Other non-monetary financial liabilities	-	-	-	-
<b>17.</b>	<b>Long term liabilities (14+15+16)</b>	<b>435.331.056</b>	<b>23.239.967</b>	<b>-</b>	<b>-</b>
<b>18.</b>	<b>Total liabilities (13+17)</b>	<b>3.526.851.618</b>	<b>187.819.050</b>	<b>431.889</b>	<b>-</b>
19.	Net asset/(liability) position of off-balance sheet derivative instruments (19a-19b)	130.032.885	6.954.262	-	-
19a.	Total amount of hedged assets	130.032.885	6.954.262	-	-
19b.	Total amount of hedged liabilities	-	-	-	-
<b>20.</b>	<b>Net foreign currency asset/(liability) position (9-18+19)</b>	<b>(1.549.340.440)</b>	<b>(83.025.929)</b>	<b>(208.466)</b>	<b>51.120.472</b>
21.	Total fair value of financial instruments used for foreign currency hedges (1 +2a+3+5+6a+7-10-11 -12a-14-15-16a)	<b>(1.679.373.325)</b>	<b>(89.980.191)</b>	<b>(208.466)</b>	<b>51.120.472</b>
21.	Export(Average Exchange Rate)	<b>1.882.609.539</b>	<b>96.661.453</b>	<b>16.185.369</b>	<b>7.466</b>
21.	Import (Average Exchange Rate)	<b>3.703.433.627</b>	<b>196.791.958</b>	<b>14.765.013</b>	<b>269.870.187</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 32 – NATURE AND LEVEL OF RISKS ARISING FROM FINANCIAL INSTRUMENTS (Cont.)****Exchange Rate Risk (Cont.)**

The table below illustrates how the Group is affected by a 10% rise or fall in foreign exchange rates. It examines solely outstanding monetary items denominated in foreign currency as of the reporting date, and highlights the ramifications of a 10% shift in foreign exchange rates at the end of the period. Positive results indicate a rise in profits and other equity items.

<b>Foreign currency sensitivity analysis table</b>				
<b>September 30, 2023</b>				
	<b>Profit/Loss</b>		<b>Equity</b>	
	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION
If the US Dollar appreciates/depreciates by 10% against TL				
1- US Dollar net assets/liabilities	(156.327.364)	156.327.364	(156.327.364)	156.327.364
2- Portion hedged against US Dollar risk (-)	-	-	-	-
<b>3- US Dollar net effect (1+2)</b>	<b>(156.327.364)</b>	<b>156.327.364</b>	<b>(156.327.364)</b>	<b>156.327.364</b>
If Euro appreciates/depreciates by 10% against TL				
4- Euro net asset/liability	709.416	(709.416)	709.416	(709.416)
5- Euro hedged portion (-)	-	-	-	-
<b>6- TL net impact (4+5)</b>	<b>709.416</b>	<b>(709.416)</b>	<b>709.416</b>	<b>(709.416)</b>
If Other appreciates/depreciates by 10% against TL				
7- Other net assets/liabilities	125.062	(125.062)	125.062	(125.062)
8- Other hedged portion (-)	-	-	-	-
<b>9- TL net effect (7+8)</b>	<b>125.062</b>	<b>(125.062)</b>	<b>125.062</b>	<b>(125.062)</b>
<b>Total (3+6+9)</b>	<b>(155.492.886)</b>	<b>155.492.886</b>	<b>(155.492.886)</b>	<b>155.492.886</b>

<b>Foreign currency sensitivity analysis table</b>				
<b>December 31, 2022</b>				
	<b>Profit/Loss</b>		<b>Equity</b>	
	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION
If the US Dollar appreciates/depreciates by 10% against TL				
1- US Dollar net assets/liabilities	(168.880.610)	168.880.610	(168.880.610)	168.880.610
2- Portion hedged against US Dollar risk (-)	-	-	-	-
<b>3- US Dollar net effect (1+2)</b>	<b>(168.880.610)</b>	<b>168.880.610</b>	<b>(168.880.610)</b>	<b>168.880.610</b>
If Euro appreciates/depreciates by 10% against TL				
4- Euro net asset/liability	(417.126)	417.126	(417.126)	417.126
5- Euro hedged portion (-)	-	-	-	-
<b>6- TL net impact (4+5)</b>	<b>(417.126)</b>	<b>417.126</b>	<b>(417.126)</b>	<b>417.126</b>
If Other appreciates/depreciates by 10% against TL				
7- Other net assets/liabilities	1.360.403	(1.360.403)	1.360.403	(1.360.403)
8- Other hedged portion (-)	-	-	-	-
<b>9- TL net effect (7+8)</b>	<b>1.360.403</b>	<b>(1.360.403)</b>	<b>1.360.403</b>	<b>(1.360.403)</b>
<b>Total (3+6+9)</b>	<b>(167.937.333)</b>	<b>167.937.333</b>	<b>(167.937.333)</b>	<b>167.937.333</b>



**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)***NOTE 33 – FINANCIAL INSTRUMENTS (FAIR VALUE AND HEDGE ACCOUNTING DISCLOSURES)****Fair Value of Financial Instruments**

The Group classifies its financial instruments carried at fair value in the consolidated financial statements according to the source of the valuation inputs for each class of financial instruments, using a three-level hierarchy.

Level 1: Valuation techniques using quoted prices in active markets for identical assets or liabilities that the Group has access to at the measurement date,

Level 2: Other valuation techniques involving inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly,

Level 3: Valuation techniques that use unobservable inputs for the asset or liability.

<b>Financial Assets (September 30, 2023)</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Derivative Assets	-	410.090.493	-
Financial Investments	1.950.658.946	-	-
<b>Financial Liabilities (September 30, 2023)</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Derivative Liabilities	-	-	-
Financial Investments	-	-	-
<b>Financial Assets (December 31, 2022)</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Derivative Assets	-	144.075.641	-
Financial Investments	1.047.908.349	-	-
<b>Financial Liabilities (December 31, 2022)</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Derivative Liabilities	-	65.554.675	-
Financial Investments	-	-	-

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

As of September 30, 2023 Notes to the Consolidated Financial Statements

*(Amounts are in Turkish Lira (TL) unless otherwise indicated.)*

---

### **NOTE 34 – EVENTS AFTER BALANCE SHEET DATE**

- To diversify Söke Değirmencilik's bakery product offerings in the targeted market, the company invested in a production facility with a closed area of 4,100 square meters built on a total area of 6,955 square meters at Çiftlik Osb Mahallesi, 4th Street, No: 1 Tekkeköy/Samsun. The lease agreement for this facility was signed on October 4, 2023, and approved by the Samsun Specialized Food Organized Industrial Zone Management on October 10, 2023. Production is scheduled to commence in the first half of 2024, where the facility will produce both "Söke" brand cookies and private-label cookies.

- At the Company's Board of Directors meeting on October 12, 2023, a unanimous resolution authorized Eren Gunhan Ulusoy to establish two companies in accordance with Malta's laws and obligations. Malta's strategic importance as an EU member state grants access to EU opportunities that will support the existing operations in international commodity trades and objectively assess investment prospects to accomplish long-term goals. Eren Gunhan Ulusoy is also authorized to manage the related processes.

- Following its strategic investment in Rudi's, Söke Değirmencilik received the "USDA Organic" product sales certificate from the Ecological Agriculture Control Organization (ETKO) on October 17, 2023. The certificate is based on the standards of the National Organic Program (NOP) of the United States Department of Agriculture, allowing Söke Değirmencilik to sell organic flour in the USA.

- With the Board of Directors meeting dated October 19, 2023, a portion of the Company's assets and liabilities will be transferred to two newly established companies, "Ulusoy Taşınmaz Geliştirme ve Ticaret Anonim Şirketi" and "Ulusoy Varlık ve Endüstriyel Gayrimenkul Yatırımları Ticaret A.Ş.", in which the Company will participate fully. Article 134, as well as other relevant articles of the Turkish Commercial Code No. 6102, and Articles 19-20 of the Corporate Tax Law No. 5520, should be considered in accordance with General Communiqué No. 1 of the KVK, the Trade Registry Regulation, Article 23, and other related provisions of the CMB, and the Capital Markets Board's "II-23." 2 Merger and Demerger statements from the Capital Markets Board and related legislation dictate that, as the sole shareholder with 100% participation in the soon-to-be-established companies, the Company will conduct the demerger process in compliance with CMB Communiqué No. II-23. 2 of the Capital Markets Board have decided to conduct the spin-off transaction with a subsidiary model, following Article 14 and Article 17 titled spin-off transactions. The partial spin-off transaction will be based on the Company's financial statements as of June 30, 2023, and an application was submitted to the Capital Markets Board on October 20, 2023.